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Introduction
The growth and development of the most common form of
breast malignancies, hormone-dependent breast cancer
(HDBC), is promoted by the presence of oestrogenic steroids.
Currently, the most widely used therapies for the treatment of
this disease focus on blocking the action of these steroids,
either by the use of selective, oestrogen receptor modulators,
such as tamoxifen, or by inhibiting their biosynthesis through
inhibition of the aromatase enzyme complex. Third-generation
aromatase inhibitors (AIs), currently finding widespread appli-
cation in the clinic, comprise the nonsteroidal compounds
anastrozole and letrozole, and the steroidal exemestane.
[1–3] Al-
though these compounds were initially used in patients for
whom tamoxifen therapy had failed, data from a number of
clinical trials suggest that AIs provide a more effective first-line
therapy against HDBC as a result of their superior efficacy and
toxicology profile.
[4–6] Of these AIs, there is evidence to suggest
that letrozole is superior to anastrozole in suppressing oestro-
gen levels in breast tissue and plasma in patients with postme-
nopausal breast cancer.
[7] It is unclear how this difference will
translate to the clinic, however, the Femara versus Anastrozole
Clinical Evaluation (FACE) trial should help to determine wheth-
er any differences in efficacy exist between these two AIs.
[8]
A promising new therapy for the treatment of HDBC has
arisen from the development of inhibitors of steroid sulfatase
(STS).
[9] This enzyme is believed to be virtually ubiquitous
Concurrent inhibition of aromatase and steroid sulfatase (STS)
may provide a more effective treatment for hormone-depen-
dent breast cancer than monotherapy against individual en-
zymes, and several dual aromatase–sulfatase inhibitors (DASIs)
have been reported. Three aromatase inhibitors with sub-
nanomolar potency, better than the benchmark agent letro-
zole, were designed. To further explore the DASI concept, a
new series of letrozole-derived sulfamates and a vorozole-
based sulfamate were designed and biologically evaluated in
JEG-3 cells to reveal structure–activity relationships. Amongst
achiral and racemic compounds, 2-bromo-4-(2-(4-cyanophen-
yl)-2-(1H-1,2,4-triazol-1-yl)ethyl)phenyl sulfamate is the most
potent DASI (aromatase: IC50=0.87 nm; STS: IC50=593 nm).
The enantiomers of the phenolic precursor to this compound
were separated by chiral HPLC and their absolute configura-
tion determined by X-ray crystallography. Following conversion
to their corresponding sulfamates, the S-(+)-enantiomer was
found to inhibit aromatase and sulfatase most potently (aro-
matase: IC50=0.52 nm; STS: IC50=280 nm). The docking of
each enantiomer and other ligands into the aromatase and sul-
fatase active sites was also investigated.
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alkyl and aryl steroid sulfates to their unconjugated and bio-
logically active forms. Primarily, STS catalyses the conversion of
oestrone sulfate, a biologically inactive steroid found at high
levels in the plasma of postmenopausal women, to oestrone.
In breast cancer tissue, it has been shown that ten times more
oestrone originates from oestrone sulfate than from androste-
nedione.
[10] In addition, STS controls the formation of dehy-
droepiandrosterone (DHEA) from DHEA-sulfate (DHEA-S). DHEA
can be subsequently converted to androst-5-ene-3b,17b-diol,
an androgen with oestrogenic properties capable of stimulat-
ing the growth of breast cancer cells in vitro
[11] and inducing
mammary tumours in vivo.
[12] The pharmacophore for irreversi-
ble STS inhibition has been identified as a substituted phenol
sulfamate ester, and a number of steroidal (e.g., oestrone-3-O-
sulfamate, also known as EMATE) and nonsteroidal inhibitors
(e.g., Irosustat, also known as STX64, BN83495) have been de-
veloped.
[9,13–14] Irosustat, discovered by our group, has been
evaluated in a phase 1 clinical trial for the treatment of post-
menopausal patients with metastatic breast cancer and has
shown promising results.
[15]
The advantages of a single chemical agent with the ability
to interact with multiple biological targets have been recently
highlighted.
[16–18] A possible application of this concept for the
treatment of HDBC would be the combination of the pharma-
cophores for both aromatase and STS inhibition into a single
molecular entity. One approach to achieve this would be inser-
tion of the pharmacophore for STS inhibition into an estab-
lished AI, whilst maintaining the features necessary for aroma-
tase inhibition. We previously reported three series of dual aro-
matase–sulfatase inhibitors (DASIs) based on different AIs: ex-
amples include, compounds 1 and 2 based on letrozole,
[19–20]
compound 3 based on YM511 (4),
[21–24] and compound 5 based
on anastrozole.
[25] In a complementary approach, we also re-
ported a series of DASIs obtained following introduction of the
pharmacophore for aromatase inhibition into a biphenyl tem-
plate primarily designed for STS inhibition (e.g, 6).
[26]
In preliminary work on the design of a prototype letrozole-
based DASI, it was hoped that dual aromatase and sulfatase in-
hibition could be achieved by replacing both para-cyano
groups present in letrozole with sulfamate groups, whilst re-
taining both the triazole and the diphenylmethane moieties
necessary for potent aromatase inhibition.
[19] A lead com-
pound, bis-sulfamate 1 exhibited IC50 values of 3044 nm for ar-
omatase and >10 mm for STS when evaluated in JEG-3 cells.
Further iterations improved inhibition of both aromatase and
sulfatase,
[20] and the most potent AI identified was ( )-2 in
which only one of the para-cyano groups is replaced with a
sulfamate group. Compound 2 inhibited aromatase and STS
with IC50 values of 3 nm and 2600 nm, respectively. The enan-
tiomers of 41, the phenolic precursor of 2, were separated by
chiral HPLC and converted into their corresponding sulfa-
mates;
[27] the R-configuration provided the most potent aroma-
tase inhibitor (R: 3.2 nm; S: 14.3 nm), whilst the S-configuration
proved to be the best STS inhibitor (S: 553 nm; R: 4633 nm).
[20]
Here, we report the further investigation of the structure–ac-
tivity relationships (SAR) of letrozole-derived DASIs by evaluat-
ing the effect on inhibitory activity of increasing linker length
between the triazole and the STS pharmacophore, and replac-
ing the para-cyano-substituted ring with a para-chloro-substi-
tuted ring. The enantiomers of one compound were separated
and their absolute configuration was determined by X-ray crys-
tallography. We also report the synthesis and in vitro inhibitory
activities of the first dual inhibitor derived from the third gen-
eration AI, vorozole.
Results and Discussion
Chemistry
All of the novel sulfamates and phenols described in this
paper were prepared according to Schemes 1–4. The final
compounds and intermediates were characterised by standard
analytical methods and, in addition, the purity of the com-
pounds tested in vitro was evaluated using HPLC. The refer-
ence AI, letrozole, was prepared by the alkylation of 1,2,4-tria-
zole with a-bromomethyl-p-tolunitrile followed by reaction
with 4-fluorobenzonitrile according to the procedure described
by Bowman et al.
[19,28] The reference STS inhibitor, STX64, was
synthesised according to the method of Woo et al.
[29]
The synthetic route for the sulfamates 11, 14 and 18 is
shown in Scheme 1. Both sulfamates 11 and 18 were prepared
from 3-bromo-4-(triisopropylsilyloxy)benzaldehyde (7)
[20] and
sulfamate 14 was prepared from (4-(bromomethyl)phenoxy)trii-
sopropylsilane (12).
[30] For 11, treatment of aldehyde 7 with 4-
chlorophenylmagnesium bromide followed by deprotection of
the phenol afforded 9. Displacement of the hydroxy group in
9 was achieved with 1,2,4-triazole in refluxing toluene to afford
10, which was converted to sulfamate 11 by reaction with an
excess of sulfamoyl chloride in N,N-dimethylacetamide (DMA)
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[31] For
the synthesis of sulfamate 14, it was envisaged that alkylation
of n-butyllithium-deprotonated
[32] 4-((1H-1,2,4-triazol-1-yl)me-
thyl)benzonitrile
[19] with (4-(chloromethyl)phenoxy)triisopropyl-
silane would provide a route to 13; this reaction failed to pro-
vide the desired product. However, when the alkylating agent
was switched to the more reactive 12, the desired product
could be obtained. Deprotection of the phenol was achieved
using tetra-n-butylammonium
fluoride and the product could
be used without further purifica-
tion. Phenol 13 was subsequent-
ly converted to sulfamate 14
using the conditions described
above. Starting from aldehyde 7,
reduction with sodium borohy-
dride and conversion of the re-
sulting benzyl alcohol to the
chloride gave compound 16.
This is a more reactive alkylating
agent than its nonbrominated
counterpart, and it was success-
fully used as the alkylating agent
for the synthesis of sulfamate 18
according to the route described
above.
The synthesis of sulfamates
22, 29, 35 and 40 is detailed in
Scheme 2. Compound 22 was
obtained in three steps from 19,
which was prepared according
to Avery et al.
[33] Reaction of 19
with 4-((1H-1,2,4-triazol-1-yl)me-
thyl)benzonitrile as described
above was followed by depro-
tection and sulfamoylation to
furnish 22. Sulfamate 29 was
prepared in a similar manner
using bromide 26, which was
itself prepared from methyl 2-(3-
bromo-4-hydroxyphenyl)acetate
23.
[23] Following triisopropylsilyl
(TIPS) protection of the phenolic
hydroxy group in 23, ester 24
was reduced with lithium boro-
hydride and the resulting benzyl
alcohol was converted to benzyl
bromide 26, and the synthesis of
29 was completed using the
steps described above. The
bottom part of Scheme 2 de-
scribes the route for the synthe-
sis of sulfamates 35 and 40.S u l -
famate 35 was synthesised from
30, which was prepared as de-
scribed by Avery et al.
[33] From
alcohol 30, Dess–Martin oxida-
tion gave aldehyde 31, which was reacted with 4-chlorophe-
nylmagnesium bromide to give 32. The alcohol was converted
to chloride 33 with thionyl chloride, and this was reacted with
1,2,4-triazole in acetone with concomitant loss of the TIPS pro-
tecting group to give 34. Finally, sulfamoylation as described
above furnished 35. Sulfamate 40 was prepared analogously
from 23 following TIPS protection of the phenol and lithium
borohydride reduction of ester 24.
Scheme 1. Reagents and conditions: a) 4-ClPhMgBr, THF, RT; b) TBAF, THF, RT; c) 1,2,4-Triazole, p-TsOH, toluene,
reflux; d) H2NSO2Cl, DMA, RT; e) NaBH4, EtOH/H2O, RT; f) SOCl2,C H 2Cl2,R T ;g )nBuLi, 4-((1H-1,2,4-triazol-1-yl)methyl)-
benzonitrile, THF,  788C!RT.
Scheme 2. Reagents and conditions: a) Triisopropylsilyl chloride, imidazole, DMF, RT; b) LiBH4, B(OMe)3,E t 2O, RT;
c) Br2, PPh3, imidazole, Et2O/CH3CN, RT; d) nBuLi, 4-((1H-1,2,4-triazol-1-yl)methyl)benzonitrile, THF,  788C!RT;
e) TBAF, THF, RT; f) H2NSO2Cl, DMA, RT; g) Dess–Martin periodinane, CH2Cl2, RT; h) 4-ClPhMgBr, THF, RT; i) SOCl2/
DMF, CH2Cl2, RT; j) 1,2,4-Triazole, K2CO3, KI, acetone, 558C.
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ing a mixture of 1-[(4-cyanophenyl)(3-bromo-4-hydroxyphenyl)-
methyl]-1H-[1,2,4]triazole
[20] and N,N-dimethylsulfamoyl chlo-
ride in N,N-diisopropylethylamine (DIPEA) (Scheme 3).
Vorozole-derived sulfamate 51 was prepared from benzoic
acid 43, which was synthesised as described by Dener et al.
[34]
from 3-methoxy-4-nitrobenzoic acid (Scheme 4). Formation of
the benzotriazole ring was achieved by treatment of 43 with a
mixture of sodium nitrite and hydrochloric acid in water. Sub-
sequent formation of methyl ester 45 and lithium borohydride
reduction gave compound 46. This approach to the synthesis
of the benzotriazole ring ensures that the methyl group is
placed on the correct nitrogen atom in the triazole ring. A
more concise route to 45 was explored via the alkylation of
methyl-1H-benzotriazole-5-carboxylate with methyl iodide in
the presence of potassium carbonate but this gave a mixture
of three regioisomers from which it was difficult to separate
the individual benzotriazol-1-yl isomers. The oxidation of alco-
hol 46 with potassium permanganate in dichloromethane
[35]
gave aldehyde 47 in moderate yields. However, excellent yields
of the aldehyde could be obtained by oxidation with the tri-
chloroisocyanuric acid/catalytic 2,2,6,6-tetramethylpiperidi-
nooxy (TEMPO) system reported by Giacomelli et al.
[36] Alde-
hyde 47 was subsequently reacted with the Grignard reagent
generated from 4-benzyloxybromobenzene to give alcohol 48.
This was converted to the corresponding chloride with thionyl
chloride and quickly reacted with 1,2,4-triazole in the presence
of potassium carbonate to give 49. Deprotection of the phenol
was achieved by catalytic hydrogenation with palladium on
carbon to give 50, and the formation of the corresponding sul-
famate was achieved using the conditions described above to
furnish 51.
Inhibition of aromatase and steroid sulfatase activity by sul-
famoylated compounds
The in vitro inhibition of aromatase and STS activity by each
sulfamate was measured in a preparation of an intact monolay-
er of JEG-3 cells. The results are reported as either IC50 values
or as a percentage of inhibition at 10 mm, and are compared to
the reference AI letrozole
[19] and the reference STS inhibitor
STX64
[21] (Table 1). The biological activities of both 2 and 52
have been reported previously.
[20]
All of the sulfamates tested in this series are potent inhibi-
tors of aromatase with IC50 values  39 nm and, in addition,
some compounds also exhibit moderate-to-potent STS inhibi-
tion. In this assay, two compounds, 22 and 29 (IC
Arom
50 =0.22
and 0.12 nm, respectively) are more potent than the reference
AI letrozole (IC
Arom
50 =0.89 nm).
Several compounds in this study contain a para-chloro-sub-
stituted phenyl ring rather than the para-cyano-substituted
ring found in letrozole and letrozole-based DASI 2. This substi-
tution is present in compounds capable of potent aromatase
Scheme 3. Reagents and conditions:a )N,N-Dimethylsulfamoyl chloride,
DIPEA, reflux.
Table 1. In vitro inhibition of the aromatase and STS activity in JEG-3 cells
by letrozole, STX64, 52, 2 and the sulfamates described herein.
Compd R
1 R
2 n IC
Arom
50 [nm]I C
STS
50 [nm]
Letrozole – – – 0.89 0.13
[a] –
STX64 – – – – 1.5 0.3
[b]
2 Br CN 0 3.0 0.1
[c] 2600 100
[c]
11 Br Cl 0 2.5 0.7 1400 234
14 H CN 1 2.8 0.2 3517 625
18 Br CN 1 0.87 0.21 593 6
22 H CN 2 0.22 0.01 >10000
29 Br CN 2 0.12 0.02 >10000
35 HC l 1 3 9  10 2233 666
40 Br Cl 1 1.4 1.1 180 26
42 – – – 23.04 2.92 >10000
51 –– – 2 9  10 >10000
52 HC N0 1 3  4
[c] 21.5%
[c,d]
[a] Data taken from Wood et al.
[19] [b] Data taken from Woo et al.
[21] [c] Data
taken from Wood et al.
[20] [d] Percent inhibition at 10 mm. Mean IC50 values  
SD were determined from incubations carried out in triplicate in a minimum
of two separate experiments.
Scheme 4. Reagents and conditions: a) NaNO2,6n HCl, H2O, 08C!RT;
b) SOCl2, MeOH, reflux; c) LiAlH4, THF, RT; d) Trichloroisocyanuric acid,
TEMPO, CH2Cl2,08C, e) 4-Benzyloxybromobenzene, Mg, THF, RT; f) SOCl2,
CH2Cl2, RT; g) 1,2,4-Triazole, KI, K2CO3, acetone, 608C; h) 10% Pd/C, THF/
MeOH, RT; i) H2NSO2Cl, DMA, RT.
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( )-vorozole (IC
Arom
50 =2.59 nm),
[37] and furthermore, a derivative
of letrozole with both para-cyano groups replaced by para-
chloro groups has been reported to inhibit aromatase activity
with an EC50 value of 8.8 nm in a rat ovarian microsome
assay.
[38] For this series, comparison of the activities of the
para-cyano-substituted compounds with their para-chloro-sub-
stituted counterparts reveals that, for the two sets of com-
pounds 2/11 and 18/40, dual inhibitory activity is retained fol-
lowing the switch in substitution (e.g., 2:I C
Arom
50 =3.0 nm,
IC
STS
50 =2600 nm,v s11:I C
Arom
50 =2.5 nm,I C
STS
50 =1400 nm). Howev-
er, for compounds 14 and 35, replacement of the para-cyano
group with a para-chloro group maintains STS inhibitory activi-
ty but is detrimental to aromatase activity (14:I C
Arom
50 =2.8 nm,
IC
STS
50 =3517 nm,v s35:I C
Arom
50 =39 nm,I C
STS
50 =2233 nm). The im-
portance of the positioning of a hydrogen-bond acceptor (e.g.,
CN, NO2) in the molecule relative to the triazole/imidazole ring
for potent aromatase inhibition has been extensively discussed
in the literature.
[39–40] Interestingly, in this series, replacement of
the cyano group with the weaker hydrogen-bond accepting
chloro substituent maintains good aromatase inhibitory activi-
ty, possibly due to a complex interaction between the hydro-
gen-bond donor in the active site, the halide and the p system
of the connecting aromatic ring.
[41]
The effect played by the linker between the aromatase and
STS pharmacophores on dual inhibitory activities is illustrated
by three series of compounds: 1) 52, 14 and 22;2 )2, 18 and
29;3 )11 and 40. In each series, lengthening the linker (n) re-
sults in an increase in aromatase inhibition; this is illustrated
by comparing compounds 2 (n=0; IC
Arom
50 =3.0 nm), 18 (n=1;
IC
Arom
50 =0.87 nm), and 29 (n=2; IC
Arom
50 =0.12 nm). This corre-
lates with the small increase in aromatase inhibition observed
in the aw-diarylalkyltriazole series of compounds with inhibito-
ry activities for 4-(3-(4-fluorophenyl)-1-(1H-1,2,4-triazol-1-yl)pro-
pyl)benzonitrile and linker extended 4-(4-(4-fluorophenyl)-1-
(1H-1,2,4-triazol-1-yl)butyl)benzonitrile reported as 0.19 mm and
0.12 mm, respectively.
[32] These finding are also in agreement
with those in a YM511-derived DASI series, with activities for 4-
(((4-cyanophenyl)(4H-1,2,4-triazol-4-yl)amino)methyl)phenyl sul-
famate and 4-(2-((4-cyanophenyl)(4H-1,2,4-triazol-4-yl)amino)e-
thyl)phenyl sulfamate being 100 nm and 2.1 nm, respectively.
[23]
A small increase in linker length is beneficial for enhanced STS
inhibition (2:I C
STS
50 =2600 nm, vs 18:I C
STS
50 =593 nm), but further
extension of the linker has a detrimental effect on inhibitory
activity (29:I C
STS
50 >10000 nm). Extending the linker length was
shown to be detrimental to STS activity in the YM511-derived
DASI series, with a decrease in activity from 227 nm for 4-(((4-
cyanophenyl)(4H-1,2,4-triazol-4-yl)amino)methyl)phenyl sulfa-
mate to >10000 nm for 4-(2-((4-cyanophenyl)(4H-1,2,4-triazol-
4-yl)amino)ethyl)phenyl sulfamate, which has one extra methyl-
ene unit in the linker. This decrease in STS inhibition could be
due to an increase in flexibility in the molecule as the linker is
extended, resulting in less favourable binding of the com-
pound in the active site.
As in our previous investigation into letrozole- and YM511-
derived DASIs, derivatives containing a halogen positioned
ortho to the sulfamate are better AIs than their nonhalogenat-
ed counterparts. This trend is exhibited in both the para-
cyano- (14:I C
Arom
50 =2.8 nm vs 18:I C
Arom
50 =0.9 nm) and para-
chloro-substituted series (35:I C
Arom
50 =39 nm vs 40:I C
Arom
50 =
1.4 nm). This and previous results suggest that the higher aro-
matase inhibition can be attributed to the increased lipophilici-
ty conferred by the halogen.
[20] Similarly, we previously discov-
ered that the presence of a halogen group ortho to the sulfa-
mate increases STS inhibitory activity, and this trend holds true
in this series for both pairs of compounds 14/18 (14:I C
STS
50 =
3517 nm vs 18:I C
STS
50 =593 nm) and 36/40. The increase in STS
inhibitory activity is reasoned to be caused by a lowering of
the pKa of the phenol, enhancing its leaving group ability. Pre-
sumably, the deleterious effect on activity caused by an in-
crease in linker length for compounds 22 and 29 is too large
for any halogen-induced increase in inhibition to be observed.
The N,N-dimethylsulfamate-containing compound 42 is a
weaker AI than its corresponding demethylated counterpart 2,
despite the increase in lipophilicity conferred by dimethylation,
which normally benefits aromatase inhibition. The weak STS in-
hibition exhibited by 42 in vitro is anticipated based on our
previous work on N,N-dimethylated sulfamates.
[13,42] For exam-
ple, despite the poor inhibitory activity against STS
[43] exhibited
by the N,N-dimethylated derivative of STX64 in vitro, this com-
pound has been shown to almost completely inhibit mouse
liver and skin STS activities 24 h after oral administration.
[44]
This suggests that N,N-demethylation may occur in vivo to pro-
vide a compound capable of STS inhibition, and it might also
be the case that, although 42 is inactive in vitro, it may act as
a prodrug of 2 in vivo. Further work is required to explore the
potential in vivo conversion of compound 42 to 2.
Compound 51 is the first reported example of a sulfamate-
containing vorozole derivative. Vorozole is a third generation,
aromatase-selective AI, that entered phase 3 clinical trials, but
further development was discontinued when no improvement
in median survival was obtained compared to megestrol ace-
tate.
[45] Nonetheless, we explored the feasibility of designing a
DASI that is structurally related to vorozole. Incorporation of
the STS inhibitory pharmacophore into the molecule was ach-
ieved by replacement of the para-chloro substituent attached
to the phenyl ring in vorozole with a sulfamate group. Com-
pound 51 exhibits good inhibitory activity against aromatase,
although it is a weaker AI than the corresponding letrozole de-
rivative 52 and, like 52, also exhibits poor STS inhibition. How-
ever, based on previous observations, the introduction of ap-
propriate substitutions onto the sulfamate-bearing ring in 51
would be expected to improve inhibitory activity against both
enzymes, indicating the feasibility of a DASI based on the voro-
zole template.
Inhibition of aromatase activity by parent phenols
The aromatase inhibition for the phenols described in this
paper is tabulated in Table 2. The loss of the sulfamate group
following irreversible inactivation of STS by a sulfamate-based
DASI will result in the formation of the corresponding phenol.
The quantity of phenol produced by this mechanism is limited
in principle once all the STS activity has been inactivated.
[46]
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circulation in plasma might provide an additional route for the
formation of the phenol. As these phenols still contain the
pharmacophore for aromatase inhibition they have the poten-
tial to act as AIs in their own right.
The most potent phenol in this series against aromatase is
28 (IC
Arom
50 =0.02 nm) and three compounds, 17, 21 and 28
(IC
Arom
50 =0.21, 0.16, 0.02 nm, respectively) are more potent than
the reference AI letrozole (IC
Arom
50 =0.89 nm) in this assay. With
the exception of 34, the phenols are either equipotent or
slightly better inhibitors of aromatase compared to their corre-
sponding sulfamates.
In common with the trends observed for their sulfamoylated
counterparts, positioning a halogen ortho to the phenol results
in an increase in aromatase inhibitory activity, as seen for ex-
ample in compounds 13 and 17 (IC
Arom
50 =2.9 nm vs 0.21 nm, re-
spectively), and lengthening the linker is also beneficial for aro-
matase inhibition, as seen for example in compounds 13 and
21 (IC
Arom
50 =2.9 nm vs 0.16 nm, respectively).
Chiral HPLC and absolute structure determination
In order to enrich the SAR for letrozole-derived DASIs with
their target proteins and to allow comparison with the inhibi-
tory activities of the enantiomers of 2, the activities of each
enantiomer of 18, one of the most promising DASIs in this cur-
rent series, were determined. To avoid any complications aris-
ing from decomposition of the sulfamate during separation,
resolution by chiral HPLC was performed with 17, the parent
phenol of the sulfamate, an approach previously used in the
preparation of the enantiomers of 2.
[20]
The literature contains a number of reports on the resolu-
tion of AIs by chiral HPLC with a particular focus on imidazole-
containing compounds: for example, fadrozole hydrochloride,
which was separated with a Chiralcel OD column.
[47] Using con-
ditions similar to those we reported previously for the separa-
tion of phenol 43, the enantiomers of phenol 17 were separat-
ed on a Chiralpak AD-H analytical column with methanol as
the mobile phase (see Experimental Section for further details).
The first enantiomer eluted from the column with a retention
time of 3.80 min (17a), whereas the second enantiomer eluted
with a retention time of 8.2 min (17b) giving greater peak sep-
aration than that previously obtained for 43. This separation
was subsequently scaled-up and successfully performed on a
Chiralpak AD-H semi-prep column to separate 700 mg of the
racemate with injections of 1.5–2.0 mL of a 20 mgmL
 1 metha-
nol solution of 17. Conversion of 17a and 17b into their corre-
sponding sulfamates was achieved with excess sulfamoyl chlo-
ride in DMA. We previously reported that the sulfamoylation
step proceeds without loss of enantiomeric purity in the prep-
aration of the enantiomers of 2, 2aand 2b.
[20] The optical rota-
tion for each enantiomer of the phenol and corresponding sul-
famate was measured (data given in the Experimental Section).
Previously, in the absence of suitable crystals of 2a,b and
41a,b for X-ray analysis, the absolute configuration of each
enantiomer had to be established using vibrational and elec-
tronic circular dichroism in conjunction with time-dependent
density functional theory calculations of their predicted prop-
erties. Fortuitously, crystals suitable for X-ray analysis could be
obtained from ethyl acetate solutions of both 17a and 17b,
and the absolute configuration of each enantiomer was deter-
mined from the X-ray crystal structure of 17a.
[48] The crystal
structure obtained for 17a is shown in Figure 1, allowing the
unambiguous elucidation of the absolute configuration of 17a
as R-( ). Figure 1 further illustrates the sheets that stack along
the b axis in the gross structure as a consequence of intermo-
lecular hydrogen bonding between the phenolic hydrogen
(H1) and N2 of a proximate triazole in the crystal: [H1 N2,
1.94  ; O1···N2, 2.744  , O1 H1···N2, 174.88]. The second C 
H···O type interaction arises between H6 in one molecule and a
triazole nitrogen (N3) from a lattice neighbour: [H6 N3, 2.34  ;
C6···N3, 3.29  ; C6 H6···N3, 172.68].
Inhibitory activities of chiral sulfamates and their parent
phenols
The difference in aromatase and STS inhibition exhibited by
each enantiomer of 18 was evaluated following separation of
the enantiomers of phenolic precursor 17 by chiral HPLC and
conversion to their corresponding sulfamates. For comparison,
the aromatase and STS inhibitory activities of each enantiomer
of 18 and the aromatase inhibitory activities of the enantio-
mers of 17 are shown in Table 3 along with those previously
obtained for the enantiomers of 2 and 41. Previous studies
have suggested that there is often a large difference in aroma-
tase inhibition observed between the enantiomers of chiral
AIs. For vorozole,
[37] there is a 32-fold difference in activity, with
the S-configuration being the most active (S-(+): IC50=1.38 nm
vs R-( ): IC50=44.2 nm) and exhibiting a similar inhibition to
the racemate (R,S-( ): IC50=2.59 nm). There is a larger 210-fold
difference in aromatase inhibitory activity between the enan-
tiomers of fadrozole hydrochloride
[47] with the S-enantiomer
Table 2. In vitro inhibition of the aromatase activity in JEG-3 cells by le-
trozole and the phenols described herein.
Compd R
1 R
2 n IC
Arom
50 [nm]
Letrozole – – – 0.89 0.13
[a]
10 Br Cl 0 2.3 0.8
13 H CN 1 2.9 0.3
17 Br CN 1 0.21 0.02
21 H CN 2 0.16 0.02
28 Br CN 2 0.02 0.01
34 HC l 1 8 0  5
39 Br Cl 1 1.8 0.5
50 – – – 3.8 1.0
[a] Data taken from Wood et al.
[19] Mean IC50 values  SD are shown, de-
termined from incubations in triplicate from two independent experi-
ments.
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680 nm). Our previous study on the enantiomers of 2 revealed
a more modest fourfold difference in aromatase inhibition for
the enantiomers (2a:I C
Arom
50 =14.3 nm vs 2b:I C
Arom
50 =3.2 nm),
whilst for STS inhibition there was a ninefold difference be-
tween the enantiomers (2a:I C
STS
50 =553 nm vs 2b:
IC
STS
50 =4633 nm).
In the current study, there is a more significant 60-
fold difference in aromatase activity between the two
enantiomers of 18 (18a:I C
Arom
50 =30.83 vs 18b:
IC
Arom
50 =0.52 nm) but a smaller difference (approxi-
mately fourfold) in STS inhibitory activity (18a:I C
STS
50 =
1150 vs 18b:I C
STS
50 =280 nm). This increase in the dif-
ference of aromatase inhibition exhibited by each
enantiomer could be a result of the increase in asym-
metry of the molecule following extension of the
linker length. Comparison of the aromatase inhibitory
activity between the enantiomers of 2 and 18 reveals
that in each case the most potent AI is the dextroro-
tatory enantiomer and that despite possessing differ-
ent absolute configuration, the same three-dimen-
sional relationship between the triazole ring and the
para-cyanophenyl ring is present in the two most
potent enantiomers, R-(+)-2b and S-(+)-18b. The
spatial disposition of the heterocyle and para-cyano-
substituted ring in 2b and 18b resembles that pres-
ent in the most potent enantiomers of the chrome-
none-based AI series,
[49] suggesting that this is the
most favourable orientation of these groups for
potent aromatase inhibition. For STS inhibition, there
is a switch in the most potent enantiomer from the
levorotatory for 2a to the dex-
trorotatory for 18b, and the
reason for this is currently un-
clear.
For the parent phenols, both
17a and 17b are more potent
AIs than their corresponding sul-
famates, which is in accordance
with the trend previously de-
scribed. There is a 36-fold differ-
ence in aromatase inhibition for
the two enantiomers, with the
best AI being S-(+)-17b. Signifi-
cantly, the best aromatase inhibi-
tory activity is obtained with the
S-(+)-enantiomer of both the
phenol and sulfamate providing
further confirmation that this is
the optimal three-dimensional
relationship between the triazole
ring and the para-cyanophenyl
ring for potent inhibition.
Molecular modelling
In order to examine the possible
interaction of 18a and 18b with amino acid residues within
the active site, these molecules were docked into the human
aromatase crystal structure (PDB: 3EQM)
[50] along with the nat-
ural substrate of the enzyme, androstenedione. For the first
time, we also report the result of the docking of letrozole into
Figure 1. a) X-ray crystal structure of 17a (CCDC deposition code: 806541); ellipsoids are
represented at 30% probability. b) Portion of extended structure present in 17a illustrat-
ing the network of intermolecular hydrogen bonding.
Table 3. In vitro inhibition of the aromatase and STS activity (nm) in JEG-3 cells by chiral sulfamates and aro-
matase inhibitory activity of their parent phenols.
Compd
Letrozole AR: 0.89 0.13
[a] –
STX64 – STS: 1.5 0.3
[b]
S-( )-41a: AR: 3.4 0.6
[c] R-(+)-41b: AR: 0.6 0.1
[c]
S-( )-2a:
S-( )-2a:
AR: 14.3 2
[c]
STS: 553 50
[c]
R-(+)-2b:
R-(+)-2b:
AR: 3.2 0.3
[c]
STS: 4633 551
[c]
R-( )-17a: AR: 4.0 0.06 S-(+)-17b: AR: 0.11 0.01
R-( )-18a:
R-( )-18a:
AR: 30.83 2.75
STS: 1150 50
S-(+)-18b:
S-(+)-18b:
AR: 0.52 0.10
STS: 280 20
[a] Data taken from Wood et al.
[19] [b] Data taken from Woo et al.
[21] [c] Data taken from Wood et al.
[21] Mean IC50
values  SD were determined from incubations carried out in triplicate in a minimum of two separate experi-
ments.
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[24] the suita-
bility of the crystal structure for use in docking studies by re-
moving the cocrystallised androstenedione from the substrate
binding site and using the docking program GOLD
[51] to dock
the steroid back in. The results of this experiment indicated
that the best pose of the docked androstenedione overlays
the crystal structure very well.
The results of the docking of letrozole and androstenedione
into the aromatase active site are shown in Figure 2. The 17-
keto oxygen atom in androstenedione is able to form a hydro-
gen bond with the backbone amide of Met374 (2.75  ), and
this interaction is mimicked by one of the benzonitrile groups
present in letrozole (bond distance=3.11  ). Additionally, for
the AI YM511, we recently reported
[24] that the predicted dock-
ing conformation of this compound places the benzonitrile
group in a similar position in the active site, and this is able to
form a hydrogen-bond interaction with Met374. Hydrogen-
bond interactions with either a benzonitrile moiety or another
group placed at a suitable position relative to the triazole/imi-
dazole ring are known to be important for potent aromatase
inhibitory activity in nonsteroidal AIs.
[39–40] The other benzoni-
trile group present in letrozole is able to interact with Ser478
(2.31  ).
The docking of 18a and 18b into the aromatase active site
is shown in Figure 2. Both 18a and 18b overlay androstene-
dione with their sulfamates positioned close to the 17-keto
group in androstenedione. In a manner similar to letrozole, the
benzonitrile groups of both 18a and 18b are able to form hy-
drogen-bond interactions with Ser478 (3.54   and 2.27  , re-
spectively), and for 18b, there is an additional interaction with
His480. There is no obvious structural explanation for the dif-
ference in aromatase inhibitory activity observed for the two
enantiomers. To date, no human aromatase crystal structure
complexed with a nonsteroidal AI has been reported. It might
be more relevant and informative to dock 18a and 18b into
such a crystal structure when it becomes available in the
future.
The docking of STX64, 18a and 18b (two poses) into the
crystal structure of STS (PDB: 1P49
[52]) is shown in Figure 3.
Compounds 18a and 18b dock in a mode that places the sul-
famate group in a satisfactory position for interaction with the
gem-diol form of formylglycine residue 75; this is the first step
in the interaction thought to be necessary for irreversible inac-
tivation of the enzyme. In addition, the sulfamate group is pre-
dicted to be able to form favourable interactions with His290
and Thr165 in the active site and for 18b with Lys368. Like
STX64, the remainder of the skeleton of 18a and 18b occupies
the hydrophobic tunnel leading to the active site. The benzoni-
trile groups of both 18a and 18b can form an interaction with
Arg98, and for 18a and one pose of 18b, interaction of their
triazole ring with Gly100 is possible, whilst for the other pose
of 18b, interaction of its triazole ring with His485 may occur.
Conclusions
A range of DASIs structurally similar to the potent clinical AI le-
trozole and one compound similar to vorozole were synthes-
ised and evaluated for aromatase and sulfatase inhibitory activ-
ity in JEG-3 cells. In order to realise molecules capable of dual
inhibition, the known pharmacophore for STS inhibition (a
phenol sulfamate ester) and the pharmacophore for aromatase
inhibition (an N-containing heterocyclic ring) were incorporat-
ed into a single molecule.
For racemic compounds, the most potent AI identified is 29
(IC
Arom
50 =0.12 nm), while the most potent inhibitor of STS is 40
(IC
STS
50 =180 nm). Consideration of the developing SAR for these
derivatives reveals that extending the linker between the aro-
matase and STS pharmacophores is beneficial for aromatase in-
hibition, but this is balanced by the detrimental effects on STS
inhibition resulting from extension of the linker beyond two
carbon atoms. As anticipated, the addition of a halogen in the
ortho position to the sulfamate group results in an increase in
both aromatase and STS inhibitory activity. Compounds capa-
Figure 2. a) The docking of androstenedione and letrozole into the human
aromatase crystal structure. Androstendione (cyan) is in the dark green pro-
tein and letrozole (pink) is in the light green protein. b) The docking of 18a
and 18b into the aromatase active site. 18a (cyan) is in the light green pro-
tein and 18b (pink) is in the dark green protein. In both figures the haeme
group is in purple with the iron represented by the orange sphere and pos-
sible hydrogen bonds are shown by dotted lines.
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following exchanging the para-cyano group for a para-chloro
substituent, suggesting that this group is able to replicate in-
teractions within the enzyme active site. Compound 51, the
first sulfamate-containing vorozole derivative, exhibits good in-
hibitory activity against aromatase meriting further investiga-
tion. Even with an IC50 value in the micromolar range for STS
inhibition, based on established precedent, it is likely that this
compound will be effective in vivo on both enzymes.
The enantiomers of 17, the phenolic precursor of 18, one of
the most potent dual inhibitors in the current study, were sep-
arated by chiral HPLC and the absolute configuration of one
enantiomer was unambiguously established using X-ray crys-
tallography. Following conversion to the corresponding sulfa-
mate and biological evaluation, it was established that there is
a 60-fold difference in aromatase inhibition, with S-(+)-18b
being the most potent. This enantiomer has the same spatial
disposition of the heterocycle and para-cyano-substituted ring
as that found in R-(+)-2b, the most potent enantiomer discov-
ered in our previous study. For STS inhibition, there is a four-
fold difference in inhibition with the most potent enantiomer
also being S-(+)-18b.
Molecular modelling studies indicate that both YM511 and
letrozole dock into the human aromatase crystal structure with
a benzonitrile group occupying a similar area of space to the
17-keto oxygen atom of androstenedione. For 18a and 18b,
the sulfamate group is predicted to occupy this same area of
space with their benzonitrile group able to form hydrogen
bonds with Ser478. The molecular modelling study suggests
no obvious structural explanation for the difference in aroma-
tase inhibitory activity of 18a and 18b. For STS, both 18a and
18b dock in a similar orientation to that of STX64.
These results further demonstrate the feasibility of designing
a DASI based on the letrozole or vorozole templates and pro-
vide a basis for continuing pre-clinical development of such
compounds for the treatment of HDBC using a multitargeted
strategy.
Experimental Section
In vitro aromatase and sulfatase assays: Biological assays were
performed essentially as described previously.
[22] The extent of in
vitro inhibition of aromatase and sulfatase activities was assessed
using intact monolayers of JEG-3 human choriocarcinoma cells,
which were chosen because these cells constitutively express both
enzymes maximally. Aromatase activity was measured using [1b-
3H]androstenedione (30 Cimmol
 1, PerkinElmer Life Sciences, Wal-
tham, MA, USA) over a 1 h period. Sulfatase activity was measured
using [6,7-
3H]E1S (50 Cimmol
 1, PerkinElmer Life Sciences) over a
1 h period. Each compound was tested in replicate incubations
(n=3) using a minimum of six concentrations of the inhibitor (0.1–
10000 nm range). Mean IC50 values  SD from two independent
experiments are shown.
Figure 3. a) The docking of STX64 (cyan) and 18a (buff) into the crystal structure of human STS. The Ca
2+ ion is depicted as a yellow sphere and FG75 is the
gem-diol form of formylglycine residue 75. b) The docking of 18b (two poses: buff and cyan).
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STX64, 18a and 18b were built and minimised using the Schroe-
dinger software running under Maestro version 9.0. The GOLD
docking program (version 5.0)
[51] was used to dock the models into
the aromatase crystal structure (PDB: 3EQM).
[50] The binding site
was defined as a 10   sphere around the androstenedione that is
present in the crystal structure. A distance constraint of 2.30   was
applied between the ligating triazole nitrogen atom of the ligand
to the haeme iron atom. The ligands were then docked to the
rigid enzyme a total of 25 times each and scored using the GOLD-
Score fitness function. To remove strain from the docked poses,
the systems were put through an energy minimisation procedure
using the Impact module of the Schroedinger software.
The crystal structure of human placental oestrone/DHEA sulfatase
(PDB: 1P49
[52]) was used for building the gem-diol form of steroid
sulfatase (STS). This involved a point mutation of the ALS75 residue
in the crystal structure to the gem-diol form of the structure using
editing tools within the Schroedinger software. The resulting struc-
ture was then minimised with the backbone atoms fixed to allow
the gem-diol and surrounding side chain atoms to adopt low
energy confirmations. GOLD was used to dock the ligands 25
times each into the rigid protein. The docked poses were scored
using the GOLDScore fitness function.
Crystallographic data: CCDC 806541 (17a) contains the supple-
mentary crystallographic data for this paper. These data can be ob-
tained free of charge from The Cambridge Crystallographic Data
Centre via http://www.ccdc.cam.ac.uk.
General methods for synthesis: All chemicals were purchased
from either Aldrich Chemical Co. (Gillingham, UK) or Alfa Aesar
(Heysham, UK). All organic solvents of AR grade were supplied by
Fisher Scientific (Loughborough, UK). Anhydrous N,N-dimethylfor-
mamide (DMF), N,N-dimethylacetamide (DMA) and tetrahydrofuran
(THF) were purchased from Aldrich. Sulfamoyl chloride was pre-
pared by an adaptation of the method of Appel and Berger
[53] and
was stored under N2 as a solution in toluene as described by Woo
et al.
[54]
Thin layer chromatography (TLC) was performed on pre-coated
aluminium plates (Merck, silica gel 60 F254). Product spots were vi-
sualised either by UV irradiation at 254 nm or by staining with
either alkaline KMnO4 solution or 5% w/v dodecamolybdophos-
phoric acid in EtOH, followed by heating. Flash column chromatog-
raphy was performed using gradient elution on either pre-packed
columns (Isolute) on a Flashmaster II system (Biotage) or on a Tele-
dyne ISCO CombiFlash Rf automated flash chromatography system
with RediSep Rf disposable flash columns.
1H and
13C NMR spectra
were recorded on either a Jeol Delta 270 MHz or a Varian Mercury
VX 400 MHz spectrometer. Chemical shifts (d) are reported in parts
per million (ppm) relative to tetramethylsilane (TMS) as an internal
standard. Coupling constants (J) are recorded to the nearest
0.1 Hz. Mass spectra were recorded at the Mass Spectrometry Ser-
vice Centre, University of Bath (UK). Fast atom bombardment (FAB)
mass spectra were measured using m-nitrobenzyl alcohol as the
matrix. Elemental analyses were performed by the Microanalysis
Service, University of Bath (UK). Melting points (mp) were deter-
mined using either a Stuart Scientific SMP3 or a Stanford Research
Systems Optimelt MPA100 and are uncorrected. Optical rotations
were measured with a machine supplied by Optical Activity Ltd
using 5 cm cells.
LC/MS was performed using a Waters 2790 machine with a ZQ Mi-
croMass spectrometer and photodiode array (PDA) detector. The
ionisation technique used was either atmospheric pressure chemi-
cal ionisation (APCI) or electrospray ionisation (ESI). A Waters “Sym-
metry” C18 column (packing: 3.5 mm, 4.6 100 mm) and gradient
elution were used (MeCN/H2O, 5:95 at 0.5 mLmin
 1!95:5 at
1 mLmin
 1 over 10 min). HPLC was undertaken using a Waters 717
machine with an autosampler and PDA detector. The column used
was either a Waters “Symmetry” C18 (packing: 3.5 mm, 4.6 
150 mm) or a Waters “Sunfire” C18 (packing: 3.5 mm, 4.6 150 mm)
with an isocratic mobile phase consisting of CH3CN/H2O (as indicat-
ed) with a flow rate of 1 mLmin
 1. Analytical chiral HPLC was per-
formed on a Chiralpak AD-H column (250 4.6 mm, 5 mm) with
MeOH as the mobile phase, a flow rate of 1.2 mLmin
 1 and a PDA
detector. Semi-preparative HPLC was performed with a Waters
2525 binary gradient module and a Chiralpak AD-H (250 20 mm)
semi-prep column with MeOH as the mobile phase at a flow rate
of 10 mLmin
 1, injecting 1.5–2.0 mL of a 20 mgmL
 1 solution and
a run time of 25 min.
Method A: Condensation of carbinols with triazole: Substrate,
1,2,4-triazole and para-toluenesulfonic acid (p-TsOH), dissolved/sus-
pended in toluene were heated at reflux with a Dean–Stark separa-
tor for 24 h. The reaction mixture was allowed to cool, and the sol-
vent was removed in vacuo.
Method B: Hydrogenation: Pd/C (10%) was added to a solution
of substrate in THF/MeOH (1:1). The solution was stirred overnight
under an H2 atmosphere (maintained using a balloon). Excess H2
was removed, and the reaction mixture was filtered through Celite,
washing with THF and MeOH, and then the solvent was removed
in vacuo.
Method C: Sulfamoylation: A solution of sulfamoyl chloride
(H2NSO2Cl) in toluene was concentrated in vacuo at 308C to furnish
a yellow oil, which solidified upon cooling in an ice bath. DMA and
substrate were subsequently added and the mixture was allowed
to warm to RT and stirred overnight. The reaction mixture was
poured into H2O and extracted with EtOAc (2 ). The organic layers
were combined, washed with H2O (4 ) and brine, dried (MgSO4),
filtered, and the solvent was removed in vacuo.
Method D: Removal of the TIPS protecting group: Tetra-n-buty-
lammonium fluoride (TBAF; 1m in THF) was added to a solution of
substrate in THF. After stirring for 15 min, H2O was added, and the
solution was treated with AcOH (3m) until colourless. The product
was extracted with EtOAc, and the combined organic layers were
washed with satd aq NaHCO3 and brine, then dried (MgSO4), fil-
tered and concentrated in vacuo.
(3-Bromo-4-(triisopropylsilyloxy)phenyl)(4-chlorophenyl)metha-
nol (8): 4-ClPhMgBr (1m in Et2O, 17.0 mL) was added dropwise to a
solution of 7
[20] (2.00 g, 5.60 mmol) in THF (20 mL). After stirring for
2 h, the reaction was quenched by addition of H2O (50 mL) and
1m aq HCl (50 mL). EtOAc (75 mL) was added, the layers were sep-
arated, and the aqueous layer was further extracted with EtOAc
(75 mL). The combined organic layers were washed with H2O
(150 mL), satd aq NaHCO3 (150 mL) and brine (150 mL), then dried
(MgSO4), filtered and concentrated in vacuo. Purification using a
Flashmaster II (EtOAc/hexane) gave 8 as a colourless oil (2.20 g,
84%):
1H NMR (270 MHz, CDCl3): d=1.08–1.38 (21H, m, 6CH3,
3CH), 2.33 (1H, d, J=3.5 Hz, OH), 5.69 (1H, d, J=3.5 Hz, CH), 6.82
(1H, d, J=8.4 Hz, ArH), 7.07 (1H, dd, J=8.4, 2.0 Hz, ArH), 7.22–7.33
(4H, m, ArH), 7.48 ppm (1H, d, J=2.0 Hz, ArH);
13C NMR (100 MHz,
[D6]DMSO): d=12.9 (3CH), 17.9 (6CH3), 74.6 (CH), 115.1 (C), 119.4
(CH), 126.5 (CH), 127.8 (2CH), 128.6 (2CH), 131.6 (CH), 133.4 (C),
137.1 (C), 141.8 (C), 152.5 ppm (C); LC/MS (APCI ): tR=3.11 min, m/
z (%): 469.0 (1) [M H]
 , 310.8 (100).
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method D using TBAF (9.4 mL), 8 (2.15 g, 4.59 mmol) and THF
(20 mL). Purification using a Flashmaster II (EtOAc/hexane) gave 9
as a cream solid (1.32 g, 92%): mp: 125.5–1288C;
1H NMR
(270 MHz,[ D 6]DMSO): d=5.61 (1H, d, J=4.2 Hz, CH), 5.94 (1H, d,
J=4.2 Hz, OH), 6.87 (1H, d, J=8.2 Hz, ArH), 7.11 (1H, dd, J=8.2,
2.0 Hz, ArH), 7.34–7.39 (4H, m, ArH), 7.42 (1H, d, J=2.0 Hz, ArH),
10.15 ppm (1H, s, OH);
13C NMR (68 MHz,[ D 6]DMSO): d=73.0 (CH),
109.4 (C), 116.6 (CH), 127.3 (CH), 128.5 (2CH), 128.6 (2CH), 131.1
(CH), 131.8 (C), 138.2 (C), 145.2 (C), 153.5 ppm (C); LC/MS (APCI ):
tR=0.89 min, m/z (%): 311.0 (80) [M H]
 ; HRMS-ESI: m/z [M H]
 
calcd for C13H9BrClO2: 310.9480, found: 310.9469.
2-Bromo-4-((4-chlorophenyl)(1H-1,2,4-triazol-1-yl)methyl)phenol
(10): As method A using 9 (0.80 g, 2.55 mmol), 1,2,4-triazole
(1.32 g, 19.1 mmol), p-TsOH (0.11 g) and toluene (200 mL). The resi-
due was dissolved in EtOAc/H2O (1:1, 300 mL), and the organic
layer was washed with H2O (3 100 mL) and brine (150 mL), then
dried (MgSO4), filtered and concetrated in vacuo. Purification using
a Flashmaster II (EtOAc/hexane) gave 10 as an oil (0.87 g, 96%);
white crystals were obtained by slow evaporation of the solvent
from a concentrated EtOAc solution: mp: 95–988C;
1H NMR
(270 MHz,[ D 6]DMSO): d=6.94 (1H, d, J=8.4 Hz, ArH), 7.03 (1H, s,
ArH), 7.08 (1H, dd, J=8.4, 2.2 Hz, ArH), 7.18 (2H, AA’BB’,A r H), 7.37
(1H, d, J=2.2 Hz, ArH), 7.44 (2H, AA’BB’,A r H), 8.08 (1H, s, NCHN),
8.60 (1H, s, NCHN), 10.51 ppm (1H, s, OH);
13C NMR (100 MHz,
[D6]DMSO): d=63.6 (CH), 109.2 (C), 116.4 (CH), 128.7 (2CH), 128.8
(CH), 129.6 (2CH), 130.6 (C), 132.6 (CH), 132.7 (C), 138.2 (C), 144.5
(CH), 152.1 (CH), 154.1 ppm (C); LC/MS (ESI ): tR=0.85 min, m/z
(%): 362.1 (95) [M H]
 ; HRMS-ESI: m/z [M H]
  calcd for
C15H10BrClN3O: 361.9690, found: 361.9700.
2-Bromo-4-((4-chlorophenyl)(1H-1,2,4-triazol-1-yl)methyl)phenyl
sulfamate (11): As method C using ClSO2NH2 (0.6m, 3.0 mL), DMA
(3 mL) and 10 (0.15 g, 0.42 mmol). Purification using a Flashmaster
II (CH2Cl2/acetone) gave 11 as a white solid (0.15 g, 82%):
1H NMR
(270 MHz,[ D 6]DMSO): d=7.20 (1H, s, CH), 7.26 (2H, AA’BB’,A r H),
7.35 (1H, dd, J=8.4, 2.2 Hz, ArH), 7.44–7.53 (3H, m, ArH), 7.61 (1H,
d, J=2.2 Hz, ArH), 8.12 (1H, s, NCHN), 8.32 (2H, s, NH2), 8.67 ppm
(1H, s, NCHN);
13C NMR (68 MHz,[ D 6]DMSO): d=63.9 (CH), 116.6
(C), 124.2 (CH), 129.4 (C), 129.5 (2CH), 130.4 (CH), 130.5 (2CH), 133.6
(C), 137.9 (C), 139.0 (C), 145.4 (CH), 147.6 (C), 152.9 ppm (CH); LC/
MS (ESI ): tR=0.89 min, m/z (%): 443.2 (20) [M H]
 ; HRMS-ESI: m/z
[M H]
  calcd for C15H11BrClN4O3S: 440.9429, found: 440.9421.
4-(2-(4-Hydroxyphenyl)-1-(1H-1,2,4-triazol-1-yl)ethyl)benzonitrile
(13): nBuLi (1.95m, 3.00 mL) was added dropwise to a cooled
( 788C) solution of 4-((1H-1,2,4-triazol-1-yl)methyl)benzonitrile
[19]
(0.95 g, 5.16 mmol) in THF (50 mL). After 30 min, a solution of 12
[30]
(2.30 g, 6.71 mmol) in THF (25 mL) was added, and the mixture
was stirred for 30 min. The reaction mixture was allowed to warm
to RT and stirred for 4 h. The reaction was quenched by cautious
addition of satd aq NH4Cl. The layers were separated and the or-
ganic was dried (MgSO4), filtered and concentrated in vacuo. The
crude intermediate was purified using a CombiFlash Rf (EtOAc/PE)
and used without further purification. Deprotection was achieved
using method D with TBAF (2.5 mL) and a solution of the inter-
mediate in THF (10 mL). Purification using a Combiflash Rf (EtOAc/
PE) gave 13 as a white solid (0.35 g, 23%): mp: 221.5–223.58C;
1H NMR (270 MHz,[ D 6]DMSO): d=3.32 (1H, dd, J=14.0, 5.8 Hz,
CHH), 3.51 (1H, dd, J=14.0, 9.6 Hz, CHH), 5.93 (1H, dd, J=9.6,
5.8 Hz, CH), 6.58 (2H, AA’BB’,A r H), 6.92 (2H, AA’BB’,A r H), 7.61 (2H,
AA’BB’,A r H), 7.83 (2H, AA’BB’,A r H), 8.00 (1H, s, NCHN), 8.56 (1H, s,
NCHN), 9.24 ppm (1H, s, OH);
13C NMR (100 MHz,[ D 6]DMSO): d=
39.3 (CH2), 63.7 (CH), 110.8 (C), 115.1 (2CH), 118.6 (C), 126.9 (C),
128.2 (2CH), 129.9 (2CH), 132.5 (2CH), 144.1 (CH), 145.0 (C), 151.7
(CH), 156.0 ppm (C); LC/MS (ESI+): tR=1.31 min, m/z (%): 291.1
(100) [M+H]
+; HRMS-ESI: m/z [M+H]
+ calcd for C17H15N4O:
291.1240, found: 291.1234; Anal. calcd for C17H14N4O: C 70.33, H
4.86, N 19.30, found: C 70.30, H 4.88, N 19.20.
4-(2-(4-Cyanophenyl)-2-(1H-1,2,4-triazol-1-yl)ethyl)phenyl sulfa-
mate (14): As method C using ClSO2NH2 (0.57m, 6.8 mL), DMA
(1 mL) and a solution of 13 (0.19 g, 0.66 mmol) in DMA (1 mL). Pu-
rification using a Combiflash Rf (CHCl3/acetone) gave 14 as a white
foam (0.19 g, 88%):
1H NMR (270 MHz,[ D 6]DMSO): d=3.49 (1H,
dd, J=14.0, 5.5 Hz, CHH), 3.68 (1H, dd, J=14.0, 9.9 Hz, CHH), 6.08
(1H, dd, J=14.0, 9.9 Hz, CH), 7.12 (2H, AA’BB’,A r H), 7.25 (2H,
AA’BB’,A r H), 7.64 (2H, AA’BB’,A r H), 7.86 (2H, AA’BB’,A r H), 7.96
(2H, s, NH2), 8.02 (1H, s, NCHN), 8.62 ppm (1H, s, NCHN);
13C NMR
(100 MHz,[ D 6]DMSO): d=39.1 (CH2), 63.1 (CH), 111.0 (C), 118.5 (C),
121.8 (2CH), 128.2 (2CH), 130.2 (2CH), 132.6 (2CH), 135.3 (C), 144.1
(C), 144.8 (CH), 148.9 (C), 151.9 ppm (CH); LC/MS (ESI+): tR=
1.27 min, m/z (%): 370.1 (100) [M+H]
+; HRMS-ESI: m/z [M+H]
+
calcd for C17H16N5O3S: 370.0968, found: 370.0958.
(3-Bromo-4-(triisopropylsilyloxy)phenyl)methanol (15): A solution
of NaBH4 (0.19 g, 5.00 mmol) in H2O (2 mL) was added dropwise to
a solution of 7 (0.70 g, 1.96 mmol) in EtOH (6 mL). After stirring for
15 min, the reaction was quenched by cautious addition of aq HCl
(3m, 15 mL), EtOAc (15 mL) and H2O (15 mL). The layers were sepa-
rated, and the aqueous was extracted with EtOAc (30 mL). The
combined organic layers were washed with H2O (2 50 mL) and
satd aq NaHCO3 (50 mL), then dried (MgSO4), filtered and concen-
trated in vacuo. Purification using a Flashmaster II (EtOAc/hexane)
gave 15 as a colourless oil (0.57 g, 81%):
1H NMR (270 MHz,
CDCl3): d=1.10–1.37 (21H, m, 6CH3,3 C H), 1.58 (1H, t, J=5.7 Hz,
OH), 4.57 (1H, d, J=5.7 Hz, CH2), 6.85 (1H, d, J=8.2 Hz, ArH), 7.13
(1H, dd, J=8.2, 2.2 Hz, ArH), 7.52 ppm (1H, d, J=2.2 Hz, ArH);
13C NMR (100 MHz, CDCl3): d=12.9 (3CH), 18.0 (6CH3), 64.4 (CH2),
115.0 (C), 119.5 (CH), 127.1 (CH), 132.2 (CH), 134.6 (C), 152.5 ppm
(C); LC/MS (ESI+): tR=2.02 min, m/z (%): 341.2 (100) [M H2O]
+.
(2-Bromo-4-(chloromethyl)phenoxy)triisopropylsilane (16): SOCl2
(0.98 g, 7.10 mmol) was added dropwise to a solution of 15
(0.51 g, 1.42 mmol) in CH2Cl2 (8 mL). After 1 h, the solvent was re-
moved in vacuo, and the residue was redissolved in CH2Cl2 (15 mL)
and evaporated; this process was repeated twice more to give 16
as a white solid (0.54 g, 100%):
1H NMR (270 MHz, CDCl3): d=
1.10–1.38 (21H, m, 6CH3,3 C H), 4.49 (2H, s, CH2), 6.83 (1H, d, J=
8.4 Hz, ArH), 7.15 (1H, dd, J=8.4, 2.5 Hz, ArH), 7.53 ppm (1H, d, J=
2.5 Hz, ArH);
13C NMR (68 MHz, CDCl3): d=13.0 (3CH), 18.0 (6CH3),
45.4 (CH2), 115.1 (C), 119.6 (CH), 128.7 (CH), 131.2 (C), 133.8 (CH),
153.2 ppm (C); LC/MS (ESI+): tR=3.30 min, m/z (%): 341.2 (40)
[M Cl]
+, 236 (90), 185 (100).
4-(2-(3-Bromo-4-hydroxyphenyl)-1-(1H-1,2,4-triazol-1-yl)ethyl)-
benzonitrile (17): nBuLi (2.12m, 3.80 mL) was added dropwise to a
cooled ( 788C) solution of 4-((1H-1,2,4-triazol-1-yl)methyl)benzoni-
trile
[19] (1.68 g, 9.13 mmol) in THF (50 mL). After 30 min, a solution
of 16 (3.79 g, 10.0 mmol) in THF (10 mL) was added, and the mix-
ture was stirred for 1 h. The reaction mixture was allowed to warm
to RT and stirred for 2 h. The reaction was quenched by cautious
addition of satd aq NH4Cl. The layers were separated, and the or-
ganic layer was dried (MgSO4), filtered and concentrated in vacuo.
The crude intermediate was purified using a Flashmaster II (EtOAc/
hexane) and used without further purification. Deprotection was
achieved using method D with TBAF (7.6 mL) and a solution of the
intermediate in THF (30 mL). Purification using a Flashmaster II
(EtOAc/PE) gave 17 as a white solid (2.04 g, 81%): mp: 186–
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1H NMR (270 MHz,[ D 6]DMSO): d=3.30–3.39 (1H, m,
CHH), 3.51 (1H, dd, J=13.9, 9.9 Hz, CHH), 5.98 (1H, dd, J=9.9,
5.7 Hz, CH), 6.74 (1H, d, J=8.2 Hz, ArH), 6.88 (1H, dd, J=8.2,
2.0 Hz, ArH), 7.35 (1H, J=2.0 Hz, ArH), 7.62 (2H, AA’BB’,A r H), 7.84
(2H, AA’BB’,A r H), 8.02 (1H, s, NCHN), 8.59 (1H, s, NCHN),
10.07 ppm (1H, br s, OH);
13C NMR (100 MHz,[ D 6]DMSO): d=39.1
(CH2), 63.8 (CH), 109.5 (C), 111.3 (C), 116.5 (CH), 119.0 (C), 128.7
(2CH), 129.4 (C), 129.7 (CH), 133.0 (2CH), 133.6 (CH), 144.6 (CH),
145.3 (C), 152.3 (CH), 153.2 ppm (C); LC/MS (ESI+): tR=1.39 min, m/
z (%): 369.0 (100) [M+H]
+; HRMS-ESI: m/z [M+H]
+ calcd for
C17H14BrN4O: 369.0346, found: 369.0334.
2-Bromo-4-(2-(4-cyanophenyl)-2-(1H-1,2,4-triazol-1-yl)ethyl)-
phenyl sulfamate (18): As method C using ClSO2NH2 (0.6m,
4.0 mL), DMA (2 mL) and 17 (0.15 g, 0.41 mmol). Purification using
a Flashmaster II (CH2Cl2/acetone) gave 18 as a white solid (0.16 g,
88%):
1H NMR (270 MHz,[ D 6]DMSO): d=3.49 (1H, dd, J=14.0,
5.5 Hz, CHH), 3.67 (1H, dd, J=14.0, 10.2 Hz, CHH), 6.12 (1H, dd, J=
10.2, 5.5 Hz, CH), 7.21 (1H, dd, J=8.6, 1.9 Hz, ArH), 7.32 (1H, d, J=
8.6 Hz, ArH), 7.62–7.68 (3H, m, ArH), 7.86 (2H, AA’BB’,A r H), 8.04
(1H, s, NCHN), 8.23 (2H, s, NH2), 8.64 ppm (1H, s, NCHN);
13C NMR
(100 MHz,[ D 6]DMSO): d=38.6 (CH2), 62.8 (CH), 111.0 (C), 115.5 (C),
118.4 (C), 122.9 (CH), 128.2 (2CH), 129.5 (C), 132.7 (2CH), 133.9 (CH),
137.1 (C), 144.3 (CH), 144.7 (C), 146.1 (C), 152.0 ppm (CH); LC/MS
(ESI ): tR=0.78 min, m/z (%): 446.1 (100) [M H]
 ; HRMS-ESI: m/z
[M+H]
+ calcd for C17H15BrN5O3S: 448.0073, found: 448.0074.
4-(1-(1H-1,2,4-Triazol-1-yl)-3-(4-(triisopropylsilyloxy)phenyl)pro-
pyl)benzonitrile (20): nBuLi (1.75m, 0.55 mL) was added dropwise
to a cooled ( 788C) solution of 4-((1H-1,2,4-triazol-1-yl)methyl)ben-
zonitrile
[19] (0.16 g, 0.87 mmol) in THF (4 mL). After 30 min, a solu-
tion of 19
[33] (0.40 g, 1.12 mmol) in THF (1 mL) was added, and the
mixture was stirred for 2 h. The reaction mixture was allowed to
warm to RT and stirred for 1 h. The reaction was quenched by cau-
tious addition of satd aq NH4Cl. The layers were separated, and the
organic layer was dried (MgSO4), filtered and concentrated in
vacuo. Purification using a Flashmaster II (EtOAc/hexane) gave 20
as a colourless oil (0.22 g, 55%):
1H NMR (270 MHz, CDCl3): d=
1.04–1.32 (21H, m, 6CH3,3 C H), 2.30–2.84 (4H, m, CH2CH2), 5.23
(1H, dd, J=9.4, 4.4 Hz, CH), 6.80 (2H, AA’BB’,A r H), 6.91 (2H,
AA’BB’,A r H), 7.37 (2H, AA’BB’,A r H), 7.62 (2H, AA’BB’,A r H), 8.02
(1H, s, NCHN), 8.05 ppm (1H, s, NCHN);
13C NMR (100 MHz, CDCl3):
d=12.6 (3CH), 17.9 (6CH3), 31.2 (CH2), 36.5 (CH2), 62.4 (CH), 112.4
(C), 118.2 (C), 120.2 (2CH), 127.6 (2CH), 129.2 (2CH), 131.7 (C), 132.7
(2CH), 143.1 (CH), 144.3(C), 152.5 (CH), 154.7 ppm (C); LC/MS
(ESI+): tR=5.11 min, m/z (%): 461.2 (80) [M+H]
+, 263.0 (100);
HRMS-ESI: m/z [M+H]
+ calcd for C27H37N4OSi: 461.2731, found:
461.2711.
4-(3-(4-Hydroxyphenyl)-1-(1H-1,2,4-triazol-1-yl)propyl)benzoni-
trile (21): As method D using TBAF (0.42 mL), 20 (0.18 g,
0.39 mmol) and THF (3 mL). Purification using a Flashmaster II
(EtOAc/hexane) gave 21 as a white foam (0.11 g, 95%):
1H NMR
(270 MHz, CDCl3): d=2.26–2.82 (4H, m, CH2CH2), 5.27 (1H, dd, J=
9.6, 5.2 Hz, CH), 6.75 (2H, AA’BB’,A r H), 6.87 (2H, AA’BB’,A r H), 7.38
(2H, AA’BB’,A r H), 7.59 (2H, AA’BB’,A r H), 8.04 (1H, s, NCHN),
8.13 ppm (1H, s, NCHN);
13C NMR (100 MHz,[ D 6]DMSO): d=30.8
(CH2), 35.9 (CH2), 61.7 (CH), 110.8 (C), 115.2 (2CH), 118.5 (C), 127.9
(2CH), 129.1 (2CH), 130.3 (C), 132.7 (2CH), 144.1 (CH), 145.3 (C),
151.9 (CH), 155.6 ppm (C); LC/MS (ESI+): tR=3.54 min, m/z (%):
305.2 (100) [M+H]
+; HRMS-ESI: m/z [M+H]
+ calcd for C18H17N4O:
305.1397, found: 305.1389.
4-(3-(4-Cyanophenyl)-3-(1H-1,2,4-triazol-1-yl)propyl)phenyl sulfa-
mate (22): As method C using ClSO2NH2 (0.5m, 5.0 mL), DMA
(3 mL) and 21 (0.14 g, 0.46 mmol). Purification using a CombiFlash
Rf (CH2Cl2/acetone) gave 22 as a white foam (0.16 g, 91%):
1H NMR
(270 MHz,[ D 6]DMSO): d=2.42–2.78 (4H, m, CH2CH2), 5.71–5.75
(1H, m, CH), 7.18 (2H, AA’BB’,A r H), 7.25 (2H, AA’BB’,A r H), 7.57
(2H, AA’BB’,A r H), 7.85 (2H, AA’BB’,A r H), 7.94 (2H, br s, NH2), 8.08
(1H, s, NCHN), 8.79 ppm (1H, s, NCHN);
13C NMR (100 MHz,
[D6]DMSO): d=31.1 (CH2), 35.4 (CH2), 61.8 (CH), 110.9 (C), 118.5 (C),
122.1 (2CH), 127.9 (2CH), 129.5 (2CH), 132.7 (2CH), 138.8 (C), 144.2
(CH), 145.2 (C), 148.5 (C), 152.0 ppm (CH); LC/MS (ESI+): tR=
1.26 min, m/z (%): 384.3 (100) [M+H]
+; HRMS-ESI: m/z [M+H]
+
calcd for C18H18N5O3S: 384.1108, found: 384.1125.
Methyl 2-(3-bromo-4-(triisopropylsilyloxy)phenyl)acetate (24):
Imidazole (8.77 g, 0.13 mol) and triisopropylsilyl chloride (TIPSCl;
14.32 g, 74.2 mmol) were sequentially added to a pale yellow solu-
tion of 23
[23] (15.80 g, 64.5 mmol) in DMF (50 mL). The reaction
mixture was stirred overnight, then poured into H2O (100 mL) and
extracted with EtOAc (3 50 mL). The combined organic extracts
were washed with H2O (3 60 mL) and brine (60 mL), then dried
(MgSO4), filtered and concentrated in vacuo. Purification using a
CombiFlash Rf (EtOAc/PE) gave 24 as a colourless oil (22.77 g,
88%):
1H NMR (270 MHz, CDCl3): d=1.07–1.37 (21H, m, 6CH3,
3CH), 3.51 (2H, s, CH2), 3.68 (3H, s, CH3), 6.81 (1H, d, J=8.3 Hz,
ArH), 7.04 (1H, dd, J=8.3, 2.2 Hz, ArH), 7.42 ppm (1H, d, J=2.2 Hz,
ArH);
13C NMR (100 MHz, CDCl3): d=12.9 (3CH), 18.0 (6CH3), 39.8
(CH2), 52.1 (CH3), 114.9 (C), 119.4 (CH), 129.5 (C), 129.0 (CH), 134.0
(CH), 152.1 (C), 171.8 ppm (C).
2-(3-Bromo-4-(triisopropylsilyloxy)phenyl)ethanol (25): LiBH4
(3.04 g, 0.14 mol) and B(OMe)3 (0.57 g, 5.84 mmol) were sequential-
ly added to a stirred solution of 24 (22.10 g, 55.1 mmol) in Et2O
(150 mL). The reaction mixture was stirred for 48 h and then dilut-
ed with Et2O (150 mL) and quenched by cautious addition of H2O
(75 mL) and HCl (3m, 75 mL). The layers were separated, and the
organic layer was washed with brine (150 mL), then dried (MgSO4),
filtered and concentrated in vacuo. Purification using a CombiFlash
Rf (EtOAc/PE) gave 25 as a colourless oil (18.72 g, 91%):
1H NMR
(270 MHz, CDCl3): d=1.09–1.39 (22H, m, 3CH,6 C H3, OH), 2.76 (2H,
t, J=6.3 Hz, CH2), 3.80 (2H, q, J=6.3 Hz, CH2OH), 6.80 (1H, d, J=
8.3 Hz, ArH), 6.98 (1H, dd, J=8.3, 2.2 Hz, ArH), 7.37 ppm (1H, d, J=
2.2 Hz, ArH);
13C NMR (100 MHz, CDCl3): d=12.9 (3CH), 18.0 (6CH3),
37.9 (CH2), 63.5 (CH2), 115.0 (C), 119.5 (CH), 128.7 (CH), 132.1 (C),
133.7 (CH), 151.5 ppm (C); LC/MS (ESI+): tR=6.14 min, m/z (%):
373.2 (100) [M+H]
+; HRMS-ESI: m/z [M+H]
+ calcd for
C17H30BrO2Si: 373.1193, found: 373.1181.
(2-Bromo-4-(2-bromoethyl)phenoxy)triisopropylsilane (26): PPh3
(5.44 g, 20.7 mmol), imidazole (1.41 g, 20.7 mmol) and Br2 (3.22 g,
20.1 mmol) were sequentially added to a solution of 25 (2.50 g,
6.70 mmol) in Et2O/CH3CN (55 mL:19 mL). After stirring for 3 h, the
reaction mixture was filtered, washing with Et2O. The organic
layers were combined and washed with brine, then dried (MgSO4),
filtered and concentrated in vacuo. Purification using a CombiFlash
Rf (EtOAc/PE) gave 26 as a colourless oil (2.58 g, 88%):
1H NMR
(270 MHz, CDCl3): d=1.08–1.37 (21H, m, 3CH,6 C H3), 3.04 (2H, t,
J=7.7 Hz, CH2), 3.50 (2H, t, J=7.7 Hz, CH2), 6.81 (1H, d, J=8.3 Hz,
ArH), 6.96 (1H, dd, J=8.3, 2.2 Hz, ArH), 7.35 ppm (1H, d, J=2.2 Hz,
ArH).
4-(3-(3-Bromo-4-(triisopropylsilyloxy)phenyl)-1-(1H-1,2,4-triazol-
1-yl)propyl)benzonitrile (27): nBuLi (1.75m, 2.63 mL) was added
dropwise to a cooled ( 788C) solution of 4-((1H-1,2,4-triazol-1-yl)-
methyl)benzonitrile
[19] (0.77 g, 4.18 mmol) in THF (25 mL). After
30 min, a solution of 26 (2.20 g, 5.05 mmol) in THF (5 mL) was
added, and the mixture was stirred for 2 h. The reaction mixture
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quenched by cautious addition of satd aq NH4Cl. The layers were
separated, and the organic was dried (MgSO4), filtered and concen-
trated in vacuo. Purification using a CombiFlash Rf (EtOAc/PE) gave
27 as a yellow oil (0.91 g, 40%):
1H NMR (270 MHz, CDCl3): d=
1.08–1.38 (21H, m, 6CH3,3 C H), 2.30–2.53 (3H, m, 3CHH), 2.72–2.82
(1H, m, CHH), 5.26 (1H, dd, J=9.6, 5.2 Hz, CH), 6.79–6.86 (2H, m,
ArH), 7.24–7.26 (1H, m, ArH), 7.39 (2H, AA’BB’,A r H), 7.62 (2H,
AA’BB’,A r H), 8.02 (1H, s, NCHN), 8.08 ppm (1H, s, NCHN);
13C NMR
(100 MHz, CDCl3): d=12.9 (3CH), 17.9 (6CH3), 30.9 (CH2), 36.4 (CH2),
62.5 (CH), 112.5 (C), 115.2 (C), 118.2 (C), 119.7 (CH), 127.6 (2CH),
128.1 (CH), 132.7 (2CH), 133.0 (CH), 133.1 (C), 143.0 (CH), 144.1 (C),
151.6 (C), 152.5 ppm (CH); LC/MS (ESI+): tR=6.62 min, m/z (%):
539.5 (100) [M+H]
+; HRMS-ESI: m/z [M+H]
+ calcd for
C27H36BrN4OSi: 539.1836, found: 539.1816.
4-(3-(3-Bromo-4-hydroxyphenyl)-1-(1H-1,2,4-triazol-1-yl)propyl)-
benzonitrile (28): As method D using TBAF (1.72 mL), 27 (0.83 g,
1.54 mmol) and THF (10 mL). Purification using a CombiFlash Rf
(CH2Cl2/acetone) gave 28 as a foam (0.46 g, 79%):
1H NMR
(270 MHz, CDCl3): d=2.20–2.80 (4H, m, CH2CH2), 5.66 (1H, dd, J=
9.6, 5.8 Hz, CH), 6.84 (1H, d, J=8.3 Hz, ArH), 6.94 (1H, dd, J=8.3,
1.9 Hz, ArH), 7.26 (1H, d, J=1.9 Hz, ArH), 7.54 (2H, AA’BB’,A r H),
7.83 (2H, AA’BB’,A r H), 8.06 (1H, s, NCHN), 8.77 (1H, s, NCHN),
10.06 ppm (1H, br s, OH);
13C NMR (100 MHz,[ D 6]DMSO): d=35.5
(CH2), 38.9 (CH2), 61.7 (CH), 109.1 (C), 110.8 (C), 116.3 (CH), 118.5 (C),
127.9 (2CH), 128.5 (CH), 132.3 (CH), 132.4 (C), 132.7 (2CH), 144.1
(CH), 145.2 (C), 151.9 (CH), 152.3 ppm (C); LC/MS (ESI+): tR=
1.35 min, m/z (%): 383.1 (100) [M+H]
+; HRMS-ESI: m/z [M+H]
+
calcd for C18H16BrN4O: 383.0502, found: 383.0497.
2-Bromo-4-(3-(4-cyanophenyl)-3-(1H-1,2,4-triazol-1-yl)propyl)-
phenyl sulfamate (29): As method C using ClSO2NH2 (0.57m,
4.0 mL), DMA (2.5 mL) and 28 (0.16 g, 0.42 mmol). Purification
using a CombiFlash Rf (CH2Cl2/acetone) gave 29 as a white solid
(0.13 g, 67%):
1H NMR (270 MHz,[ D 6]DMSO): d=2.36–2.72 (4H, m,
2CH2), 5.74 (1H, dd, J=9.2, 5.2 Hz, CH), 7.24 (1H, dd, J=8.3, 2.2 Hz,
ArH), 7.38 (1H, d, J=8.3 Hz, ArH), 7.53–7.59 (3H, m, ArH), 7.85 (2H,
AA’BB’,A r H), 8.06 (1H, s, NCHN), 8.21 (2H, br s, NH2), 8.79 ppm
(1H, s, NCHN);
13C NMR (100 MHz,[ D 6]DMSO): d=30.8 (CH2), 35.1
(CH2), 61.9 (CH), 110.9 (C), 115.7 (C), 118.5 (C), 123.1 (CH), 128.0
(2CH), 128.8 (CH), 132.7 (2CH), 133.1 (CH), 140.7 (C), 144.1 (C), 145.1
(CH), 145.7 (C), 151.9 ppm (CH); LC/MS (ESI+): tR=1.30 min, m/z
(%): 462.0 (100) [M+H]
+; HRMS-ESI: m/z [M+H]
+ calcd for
C18H17BrN5O3S: 462.0230, found: 462.0216.
2-(4-(Triisopropylsilyloxy)phenyl)acetaldehyde (31): A solution of
30
[33] (0.25 g, 0.85 mmol) in CH2Cl2 (1 mL) was added to a suspen-
sion of Dess–Martin reagent (0.40 g, 0.94 mmol) in CH2Cl2 (5 mL).
After stirring for 1 h, Et2O (5 mL), satd aq NaHCO3 (5 mL) and satd
aq Na2S2O3 (5 mL) were added and stirring continued for 10 min.
The layers were separated, and the aqueous layer was extracted
with Et2O (10 mL). The combined organic layers were washed with
satd aq NaHCO3 (20 mL), H2O (20 mL) and brine (20 mL), then dried
(MgSO4), filtered and concentrated in vacuo. Purification using a
CombiFlash Rf (EtOAc/PE) gave 31 as a yellow oil (0.20 g, 81%):
1H NMR (270 MHz, CDCl3): d=1.05–1.31 (21H, m, 3CH,6 C H3), 3.59
(2H, d, J=2.2 Hz, CH2), 6.86 (2H, AA’BB’,A r H), 7.05 (2H, AA’BB’,
ArH), 9.70 ppm (1H, t, J=2.5 Hz, CHO);
13C NMR (100 MHz, CDCl3):
d=12.7 (3CH), 18.0 (6CH3), 49.9 (CH2), 120.5 (2CH), 124.1 (C), 130.7
(2CH), 155.6 (C), 199.9 ppm (CH).
1-(4-Chlorophenyl)-2-(4-(triisopropylsilyloxy)phenyl)ethanol (32):
4-ClPhMgBr (1m in Et2O, 8.25 mL) was added to a solution of 31
(1.20 g, 4.10 mmol) in Et2O (20 mL). After stirring for 2 h, the reac-
tion was quenched by addition of H2O (10 mL) and 2m HCl
(10 mL). The product was extracted with Et2O (2 30 mL), and the
combined organic layers were washed with brine (40 mL), then
dried (MgSO4), filtered and concentrated in vacuo. Purification
using a CombiFlash Rf (EtOAc/PE) gave 32 as a white solid (2.09 g,
90%): mp: 71–738C;
1H NMR (270 MHz, CDCl3): d=1.06–1.32 (21H,
m, 3CH,6 C H3), 1.99 (1H, d, J=3.0 Hz, OH), 2.86–2.93 (2H, m, CH2),
4.76–4.86 (1H, m, CH), 6.79 (2H, AA’BB’,A r H), 6.95 (2H, AA’BB’,
ArH), 7.14–7.32 ppm (4H, m, ArH);
13C NMR (100 MHz, CDCl3): d=
12.6 (3CH), 17.9 (6CH3), 45.3 (CH2), 74.7 (CH), 120.0 (2CH), 127.3
(2CH), 128.4 (2CH), 129.6 (C), 130.4 (2CH), 133.1 (C), 142.1 (C),
154.9 ppm (C); HRMS-ESI: m/z [M+Na]
+ calcd for C23H32BrClNaO2Si:
505.0936, found: 505.0920.
(4-(2-Chloro-2-(4-chlorophenyl)ethyl)phenoxy)triisopropylsilane
(33): SOCl2 (1.90 g, 1.01 mmol) and DMF (5 drops) were added to a
solution of 32 (1.62 g, 4.00 mmol) in CH2Cl2 (40 mL). After 1 h, the
solvent was removed in vacuo, the residue was redissolved in
CH2Cl2, and the process was repeated. Purification using a Combi-
Flash Rf (EtOAc/PE) gave 33 as a yellow oil (1.55 g, 92%):
1H NMR
(270 MHz, CDCl3): d=1.07–1.31 (21H, m, 3CH,6 C H3), 3.18 (1H, dd,
J=13.8, 7.7 Hz, CHH), 3.34 (1H, dd, J=13.8, 6.9 Hz, CHH), 4.94 (1H,
t, J=6.6 Hz, CH), 6.75 (2H, AA’BB’,A r H), 6.86 (2H, AA’BB’,A r H),
7.15–7.29 ppm (4H, m, ArH);
13C NMR (68 MHz, CDCl3): d=12.7
(3CH), 18.0 (6CH3), 46.1 (CH2), 63.4 (CH), 120.0 (2CH), 128.6 (2CH),
128.7 (2CH), 129.5 (C), 130.5 (2CH), 134.0 (C), 139.6 (C), 155.1 ppm
(C).
4-(2-(4-Chlorophenyl)-2-(1H-1,2,4-triazol-1-yl)ethyl)phenol (34):
1,2,4-Triazole (0.63 g, 9.13 mmol), K2CO3 (0.60 g, 4.35 mmol) and KI
(0.060 g, 0.36 mmol) were sequentially added to a solution of 33
(1.54 g, 3.64 mmol) in acetone (70 mL). The reaction mixture was
heated at 558C and monitored by TLC with additional portions of
triazole added when required. After 4 d, the reaction mixture was
allowed to cool, and the solvent was removed in vacuo. The resi-
due was redissolved in H2O/EtOAc (1:1, 160 mL), the layers were
separated, and the aqueous layer extracted with EtOAc (80 mL).
The organic layers were combined, washed with brine (100 mL),
then dried (MgSO4), filtered and concentrated in vacuo. Purification
using a CombiFlash Rf (PE/EtOAc) gave 34 as a white crystalline
solid (0.53 g, 49%): mp: 99–1018C;
1H NMR (270 MHz,[ D 6]DMSO):
d=3.29 (1H, dd, J=14.0, 5.8 Hz, CHH), 3.49 (1H, dd, J=14.0,
9.6 Hz, CHH), 5.83 (1H, dd, J=9.6, 5.8 Hz, CH), 6.58 (2H, AA’BB’,
ArH), 6.91 (2H, AA’BB’,A r H), 7.39–7.50 (4H, m, ArH), 7.98 (1H, s,
NCHN), 8.55 (1H, s, NCHN), 9.24 ppm (1H, s, OH);
13C NMR
(100 MHz,[ D 6]DMSO): d=39.5 (CH2), 63.5 (CH), 115.0 (2CH), 127.2
(C), 128.5 (2CH), 129.1 (2CH), 129.9 (2CH), 132.6 (C), 138.8 (C), 143.8
(CH), 151.5 (CH), 155.9 ppm (C); LC/MS (ESI+): tR=1.54 min, m/z
(%): 300.2 (100) [M+H]
+, 231.1 (70); HRMS-ESI: m/z [M+H]
+ calcd
for C16H15ClN3O: 300.0898, found: 300.0890; Anal. calcd for
C16H14ClN3O: C 64.11, H 4.71, N 14.02, found: C 64.20, H 4.72, N
14.00.
4-(2-(4-Chlorophenyl)-2-(1H-1,2,4-triazol-1-yl)ethyl)phenyl sulfa-
mate (35): As method C using ClSO2NH2 (0.57m, 6.0 mL), DMA
(2.5 mL) and 34 (0.20 g, 0.67 mmol). Purification using a Combi-
Flash Rf (CH2Cl2/acetone) gave 35 as a white foam (0.22 g, 88%):
1H NMR (270 MHz,[ D 6]DMSO): d=3.45 (1H, dd, J=14.0, 5.8 Hz,
CHH), 3.66 (1H, dd, J=14.0, 9.9 Hz, CHH), 5.97 (1H, dd, J=9.9,
5.8 Hz, CH), 7.11 (2H, AA’BB’,A r H), 7.24 (2H, AA’BB’,A r H), 7.41–7.52
(4H, m, ArH), 7.94 (2H, s, NH2), 7.99 (1H, s, NCHN), 8.59 ppm (1H, s,
NCHN);
13C NMR (100 MHz,[ D 6]DMSO): d=40.2 (CH2), 62.9 (CH2),
121.8 (2CH), 128.6 (2CH), 129.1 (2CH), 130.2 (2CH), 132.7 (C), 135.6
(C), 138.6 (C), 143.8 (CH), 148.8 (C), 151.7 ppm (CH); LC/MS (ESI+):
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+; HRMS-ESI: m/z [M+
H]
+ calcd for C16H16ClN4O3S: 379.0626, found: 379.0612.
2-(3-Bromo-4-(triisopropylsilyloxy)phenyl)acetaldehyde (36):A
solution of 25 (4.00 g, 10.7 mmol) in CH2Cl2 (6 mL) was added to a
suspension of Dess–Martin reagent (5.46 g, 12.9 mmol) in CH2Cl2
(60 mL). After stirring for 1 h, Et2O (100 mL), satd aq NaHCO3
(100 mL) and satd aq Na2S2O3 (100 mL) were added and stirring
continued for 10 min. The layers were separated, and the aqueous
layer was extracted with Et2O (100 mL). The combined organic
layers were washed with satd aq NaHCO3 (20 mL), H2O (20 mL) and
brine (20 mL), then dried (MgSO4), filtered and concentrated in
vacuo. Purification using a CombiFlash Rf (EtOAc/PE) gave 36 as a
colourless oil (2.91 g, 73%);
1H NMR (270 MHz, CDCl3): d=1.08–
1.37 (21H, m, 3CH,6 C H3), 3.57 (2H, d, J=2.2 Hz, CH2), 6.86 (1H, d,
J=8.5 Hz, ArH), 6.97 (1H, dd, J=8.3, 2.2 Hz, ArH), 7.37 (1H, d, J=
2.2 Hz, ArH), 9.70 ppm (1H, t, J=2.2 Hz, CHO);
13C NMR (100 MHz,
CDCl3): d=13.0 (3CH), 18.1 (6CH3), 49.3 (CH2), 115.4 (C), 119.9 (CH),
125.4 (C), 129.5 (CH), 134.5 (CH), 152.5 (C), 199.1 ppm (CH).
2-(3-Bromo-4-(triisopropylsilyloxy)phenyl)-1-(4-chlorophenyl)e-
thanol (37): 4-ClPhMgBr (1m in Et2O, 15.5 mL) was added to a so-
lution of 36 (2.85 g, 7.68 mmol) in Et2O (60 mL). After stirring for
2 h, the reaction was quenched by addition of H2O (30 mL) and
2m HCl (30 mL). The product was extracted with Et2O (2 75 mL),
and the combined organic layers were washed with brine
(100 mL), then dried (MgSO4), filtered and concentrated in vacuo.
Purification using a CombiFlash Rf (EtOAc/PE) gave 37 as white
solid (2.66 g, 72%): mp: 75–788C;
1H NMR (270 MHz, CDCl3): d=
1.06–1.36 (21H, m, 3CH,6 C H3), 1.96 (1H, d, J=3.0 Hz, OH), 2.86
(2H, d, J=6.9 Hz, CH2), 4.82 (1H, td, J=6.9, 3.0 Hz, CH), 6.77 (1H, d,
J=8.3 Hz, ArH), 6.86 (1H, dd, J=8.3, 2.2 Hz, ArH), 7.18–7.35 ppm
(5H, m, ArH);
13C NMR (100 MHz, CDCl3): d=12.9 (3CH), 18.0
(6CH3), 44.8 (CH2), 74.6 (CH), 115.0 (C), 119.5 (CH), 127.3 (2CH),
128.5 (2CH), 129.3 (CH), 131.1 (C), 133.3 (C), 134.1 (CH), 141.9 (C),
151.8 ppm (C); LC/MS (ESI+): tR=2.54 min, m/z (%): 427.3 (100)
[M+Na]
+; HRMS-ESI: m/z [M+Na]
+ calcd for C23H33ClNaO2Si:
427.1831, found: 427.1828.
(2-Bromo-4-(2-chloro-2-(4-chlorophenyl)ethyl)phenoxy)triisopro-
pylsilane (38): SOCl2 (2.44 g, 20.5 mmol) and DMF (5 drops) were
added to a solution of 37 (2.48 g, 5.12 mmol) in CH2Cl2 (50 mL).
After stirring for 2 h, the solvent was removed in vacuo, the resi-
due was redissolved in CH2Cl2, and the process was repeated. Pu-
rification using a CombiFlash Rf (EtOAc/PE) gave 38 as a colourless
oil (2.11 g, 82%);
1H NMR (270 MHz, CDCl3): d=1.06–1.35 (21H, m,
3CH,6 C H3), 3.13 (1H, dd, J=14.0, 7.2 Hz, CHH), 3.26 (1H, dd, J=
14.0, 7.2 Hz, CHH), 4.91 (1H, t, J=7.2 Hz, CH), 6.73–6.75 (2H, m,
ArH), 7.18–7.32 ppm (5H, m, ArH);
13C NMR (68 MHz, CDCl3): d=
13.0 (3CH), 18.1 (6CH3), 45.5 (CH2), 63.0 (CH), 112.5 (C), 119.5 (2CH),
128.6 (2CH), 128.7 (CH), 128.8 (C), 129.4 (CH), 130.8 (C), 134.2 (CH),
139.3 (C), 152.0 ppm (C).
2-Bromo-4-(2-(4-chlorophenyl)-2-(1H-1,2,4-triazol-1-yl)ethyl)phe-
nol (39): 1,2,4-Triazole (1.41 g, 20.43 mmol), K2CO3 (0.68 g,
4.93 mmol) and KI (0.067 g, 0.40 mmol) were sequentially added to
a solution of 38 (2.04 g, 4.08 mmol) in acetone (80 mL). The reac-
tion mixture was heated at 558C for 48 h then allowed to cool,
and the solvent was removed in vacuo. The residue was redis-
solved in H2O/EtOAc (1:1, 160 mL), the layers were separated, and
the aqueous layer extracted with EtOAc (80 mL). The combined or-
ganic layers were washed with brine (100 mL), then dried (MgSO4),
filtered and concentrated in vacuo. Purification using a CombiFlash
Rf (PE/EtOAc) and then (CH2Cl2/acetone) gave 39 as a white foam
(0.25 g, 16%):
1H NMR (270 MHz,[ D 6]DMSO): d=3.27–3.34 (1H, m,
CHH), 3.49 (1H, dd, J=13.8, 10.0 Hz, CHH), 5.86 (1H, dd, J=9.9,
5.8 Hz, CHH), 6.73 (1H, d, J=8.3 Hz, ArH), 6.87 (1H, dd, J=8.3,
1.9 Hz, ArH), 7.32 (1H, d, J=1.9 Hz, ArH), 7.39–7.50 (4H, m, ArH),
7.98 (1H, s, NCHN), 8.55 (1H, s, NCHN), 10.06 ppm (1H, s, OH);
13C NMR (100 MHz,[ D 6]DMSO): d=38.9 (CH2), 63.1 (CH), 109.0 (C),
116.0 (CH), 128.5 (2CH), 129.1 (2CH), 129.2 (CH), 129.3 (CH), 132.7
(C), 133.1 (CH), 138.6 (C), 143.9 (CH), 151.6 (CH), 152.6 ppm (C); LC/
MS (ESI+): tR=1.70 min, m/z (%): 378.0 (100) [M+H]
+; HRMS-ESI:
m/z [M+H]
+ calcd for C16H14BrClN3O: 378.0003, found: 377.9993.
2-Bromo-4-(2-(4-chlorophenyl)-2-(1H-1,2,4-triazol-1-yl)ethyl)-
phenyl sulfamate (40): As method C using ClSO2NH2 (0.57m,
4.5 mL), DMA (1.5 mL) and a solution of 39 (0.15 g, 0.40 mmol) in
DMA (1 mL). Purification using a CombiFlash Rf (CH2Cl2/acetone)
gave 40 as a white foam (0.13 g, 71%):
1H NMR (270 MHz,
[D6]DMSO): d=3.45 (1H, dd, J=14.0, 5.8 Hz, CHH), 3.65 (1H, dd,
J=14.0, 10.2 Hz, CHH), 6.01 (1H, dd, J=10.2, 5.8 Hz, CH), 7.20 (1H,
dd, J=8.5, 1.4 Hz, ArH), 7.31 (1H, d, J=8.5 Hz, ArH), 7.42–7.52 (4H,
m, ArH), 8.01 (1H, s, NCHN), 8.59 (1H, s, NCHN), 8.24 (2H, s, NH2),
8.61 ppm (1H, s, NCHN);
13C NMR (100 MHz,[ D 6]DMSO): d=38.8
(CH2), 62.5 (CH2), 115.4 (C), 122.8 (CH), 128.6 (2CH), 129.1 (2CH),
129.5 (CH), 132.8 (C), 133.9 (CH), 137.3 (C), 138.4 (C), 143.9 (CH),
146.1 (C), 151.7 ppm (CH); LC/MS (ESI+): tR=1.42 min, m/z (%):
457.1 (100) [M+H]
+; HRMS-ESI: m/z [M+H]
+ calcd for
C16H15BrClN4O3S: 456.9731, found: 456.9714.
2-Bromo-4-((4-cyanophenyl)(1H-1,2,4-triazol-1-yl)methyl)phenyl
dimethylsulfamate (42): N,N-Dimethylsulfamoyl chloride (0.60 g,
4.16 mmol) was added to a suspension of 41 (0.25 g, 0.70 mmol) in
N,N-diisopropylethylamine (DIPEA; 5 mL). After heating at reflux for
1 h, the reaction mixture was allowed to cool, diluted with H2O
and EtOAc, and then poured into 3m HCl (100 mL). The layers
were separated, and the organic layer was washed with H2O
(50 mL) and satd aq NaHCO3 (50 mL), then dried (MgSO4), filtered
and concentrated in vacuo. Purification using a Flashmaster II
system (hexane/EtOAc) gave 42 as a light brown oil (0.11 g, 34%):
1H NMR (270 MHz, CDCl3): d=3.08 (6H, s, 2CH3), 6.71 (1H, s, CH),
7.13 (1H, dd, J=8.4, 2.3 Hz, ArH), 7.22–7.24 (2H, m, ArH), 7.41 (1H,
d, J=2.3 Hz, ArH), 7.53 (1H, d, J=8.4 Hz, ArH), 7.69 (2H, AA’BB’,
ArH), 8.04 (1H, s, NCHN), 8.05 ppm (1H, s, NCHN);
13C NMR
(100 MHz,[ D 6]DMSO): d=38.5 (2CH3), 63.4 (CH), 111.2 (C), 115.6
(C), 118.5 (C), 123.5 (CH), 128.9 (2CH), 129.4 (CH), 132.8 (2CH), 133.5
(CH), 138.2 (C), 143.6 (C), 145.1 (CH), 146.6 (C), 152.5 ppm (CH); LC/
MS (ESI ): tR=4.23 min, m/z (%): 462.3 (100) [M H]
 ; HRMS-FAB:
m/z [M+H]
+ calcd for C18H17BrN5O3S: 462.0230, found: 462.0220.
1-Methyl-1H-benzo[d][1,2,3]triazole-6-carboxylic acid (44): NaNO2
(0.16 g, 2.32 mmol) dissolved in a small amount of H2O was added
to a mixture of 43
[34] (0.26 g, 1.57 mmol) and 6n HCl (2 mL) at 08C.
After 5 min, the reaction was allowed to warm to RTand stirred for
3h .H 2O (20 mL) and EtOAc (20 mL) were added, the layers were
separated, and the aqueous layer was extracted with EtOAc
(20 mL). The combined organic layers were dried (MgSO4), filtered
and concentrated in vacuo. Compound 44 was obtained as a
brown solid and used without further purification (0.23 g, 82%):
1H NMR (270 MHz,[ D 6]DMSO): d=4.39 ppm (3H, s, CH3), 7.92–7.97
(1H, m, ArH and CH), 8.15–8.09 (1H, m, ArH), 8.50 (1H, s, ArH); LC/
MS (ESI+): tR=0.77 min, m/z (%): 175.5 (100) [M H]
 .
Methyl 1-methyl-1H-benzo[d][1,2,3]triazole-6-carboxylate (45):
SOCl2 (0.62 g, 4.52 mmol) added to a suspension of 44 (0.20 g,
1.13 mmol) in MeOH (15 mL), and the resulting mixture was
heated at reflux overnight. The mixture was allowed to cool, and
the solvent was removed in vacuo. Purification using a Flashmaster
II (EtOAc/hexane) gave 45 as a cream solid (0.18 g, 83%):
1H NMR
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7.92–7.98 (1H, m, ArH), 8.13–8.18 (1H, m, ArH), 8.55 ppm (1H, s,
ArH); LC/MS (ESI+): tR=0.87 min, m/z (%): 191.9 (100) [M+H]
+,
159.7 (25).
(1-Methyl-1H-benzo[d][1,2,3]triazole-6-yl)methanol (46): A solu-
tion of 45 (1.88 g, 9.84 mmol) in THF (25 mL) was added to a sus-
pension of LiAlH4 (0.75 g, 19.7 mmol) in THF (60 mL). After stirring
for 20 min, the reaction was quenched by addition of EtOAc
(10 mL), H2O (10 mL) and 3m HCl (50 mL). The product was extract-
ed with EtOAc (2 75 mL), and the combined organics were
washed with satd aq NaHCO3 (2 100 mL), then dried (MgSO4), fil-
tered and concentrated in vacuo. Purification using a Flashmaster II
(EtOAc/hexane) gave 46 as pale yellow crystals (1.07 g, 67%): mp:
70–728C;
1H NMR (270 MHz, CDCl3): d=4.11 (3H, s, CH3), 4.82 (2H,
s, CH2), 4.87 (1H, br s, OH), 7.21 (1H, d, J=8.8 Hz, ArH), 7.46 (1H, s,
ArH), 7.76 ppm (1H, d, J=8.8 Hz, ArH); LC/MS (ESI+): tR=0.88 min,
m/z (%): 163.9 (100) [M+H]
+.
1-Methyl-1H-benzo[d][1,2,3]triazole-6-carbaldehyde (47): Tri-
chloroisocyanuric acid (0.81 g, 3.49 mmol) was added to a solution
of 46 (0.54 g, 3.31 mmol) in CH2Cl2 (10 mL). The solution was
cooled to 08C, TEMPO (0.006 g, 0.038 mmol) was added, the reac-
tion mixture was stirred for 10 min and then filtered through
Celite. The filtrate was washed with 20% aq Na2CO3,1 n HCl and
brine, then dried (MgSO4), filtered and concentrated in vacuo to
give 47 as a white solid used without further purification (0.50 g,
94%): mp: 148.5–1518C;
1H NMR (270 MHz,[ D 6]DMSO): d=4.42
(3H, s, CH3), 7.89 (1H, dd, J=8.5, 1.4 Hz, ArH), 8.21 (1H, d, J=
8.5 Hz, ArH), 8.56 (1H, d, J=1.4 Hz, ArH), 10.19 ppm (1H, s, CHO);
LC/MS (ESI+): tR=0.90 min, m/z (%): 161.9 (100) [M+H]
+.
(4-(Benzyloxy)phenyl)(1-methyl-1H-benzo[d][1,2,3-triazole-6-yl)-
methanol (48): A solution of 4-benzyloxybromobenzene (1.35 g,
5.13 mmol) in THF (1 mL) was added in small portions to a suspen-
sion of Mg (0.11 g, 4.58 mmol) in THF (0.5 mL) containing a crystal
of I2. Heating was used when required until the preparation of the
Grignard reagent was complete. This reagent (4 equiv) were added
to a suspension of 47 (0.050 g, 0.31 mmol) in THF (1 mL). After stir-
ring overnight, H2O (5 mL) and HCl (1m, 5 mL) were added, and
the product was extracted with EtOAc (2 20 mL). The combined
organic layers were washed with satd aq NaHCO3 (20 mL) and
brine (20 mL), then dried (MgSO4), filtered and concentrated in
vacuo. Purification using a Flashmaster II (EtOAc/hexane) gave 48
as a white crystalline solid (0.095 g, 89%): mp: 131.5–133.58C;
1H NMR (270 MHz,[ D 6]DMSO): d=4.30 (3H, s, CH3), 5.06 (2H, s,
CH2), 5.85 (1H, d, J=3.9 Hz, CH), 6.06 (1H, d, J=3.9 Hz, OH), 6.93
(2H, m, AA’BB’,A r H), 7.25–7.45 (8H, m, ArH), 7.87–7.94 ppm (2H,
m, ArH);
13C NMR (100 MHz,[ D 6]DMSO): d=34.1 (CH3), 69.1 (CH2),
73.8 (CH), 106.8 (CH), 114.5 (2CH), 118.6 (CH), 123.2 (CH), 127.6
(2CH), 127.7 (2CH), 127.8 (CH), 128.4 (2CH), 133.4 (C), 137.2 (C),
137.7 (C), 144.3 (C), 145.6 (C), 157.3 ppm (C); LC/MS (ESI+): tR=
1.64 min, m/z (%): 346.6 (100) [M+H]
+; HRMS-ESI: m/z [M+H]
+
calcd for C21H20N3O2: 346.1550, found: 346.1534.
6-((4-(Benzyloxy)phenyl)(1H-1,2,4-triazol-1-yl)methyl)-1-methyl-
1H-benzo[d][1,2,3]triazole (49): SOCl2 (0.1 mL) was added to a so-
lution of 48 (0.090 g, 0.26 mmol) in CH2Cl2 (3 mL). After stirring for
2 h, the solvent was removed in vacuo and the residue was dis-
solved in acetone (5 mL). 1,2,4-Triazole (0.036 g, 0.52 mmol), KI
(0.002 g, 0.012 mmol) and K2CO3 (0.11 g, 0.80 mmol) were added,
and the reaction mixture was stirred at 608C overnight. H2O
(10 mL) was added, and the product was extracted with EtOAc (2 
10 mL). The combined organic layers were washed with H2O
(20 mL), 1m aq NaOH (20 mL) and brine (20 mL), then dried
(MgSO4), filtered and concentrated in vacuo. Purification using a
Flashmaster II (EtOAc/hexane) gave 49 as a yellow solid (0.061 g,
76%):
1H NMR (400 MHz,[ D 6]DMSO): d=4.25 (3H, s, CH3), 5.09
(2H, s, CH2), 7.02 (2H, AA’BB’,A r H), 7.20 (1H, s, CH), 7.22–7.45 (8H,
m, ArH), 7.65 (1H, s, ArH), 8.02 (1H, d, J=9.0 Hz, ArH), 8.09 (1H, s,
NCHN), 8.61 ppm (1H, s, NCHN);
13C NMR (100 MHz,[ D 6]DMSO):
d=34.2 (CH3), 65.1 (CH), 69.3 (CH2), 109.6 (CH), 114.9 (2CH), 119.3
(CH), 124.3 (CH), 127.8 (2CH), 127.9 (CH), 128.5 (2CH), 129.6 (2CH),
130.8 (C), 133.3 (C), 136.9 (C), 138.8 (C), 144.5 (CH), 144.6 (C), 152.0
(CH), 158.2 ppm (C); LC/MS (ESI+): tR=1.62 min, m/z (%): 395.6
(100) [M]
+; HRMS-ESI: m/z [M+H]
+ calcd for C23H21N6O: 397.1771,
found: 397.1756.
4-((1-Methyl-1H-benzo[d][1,2,3]triazole-6-yl)(1H-1,2,4-triazol-1-
yl)methyl)phenol (50): As method B using Pd/C (30 mg), 49
(0.28 g, 0.71 mmol) and THF/MeOH (1:1, 20 mL). Purification using
a Flashmaster II (CH2Cl2/MeOH) gave 50 as a white solid (0.21 g,
97%):
1H NMR (270 MHz,[ D 6]DMSO): d=4.25 (3H, s, CH3), 6.75
(2H, AA’BB’,A r H), 7.09 (2H, AA’BB’,A r H), 7.16 (1H, s, CH), 7.27 (1H,
d, J=8.5 Hz, ArH), 7.61 (1H, s, ArH), 8.02 (1H, d, J=8.5 Hz, ArH),
8.08 (1H, s, NCHN), 8.56 (1H, s, NCHN), 9.63 ppm (1H, s, OH);
13C NMR (100 MHz,[ D 6]DMSO): d=34.2 (CH3), 65.4 (CH), 109.5
(CH), 115.4 (2CH), 119.2 (CH), 124.3 (CH), 128.8 (C), 129.6 (2CH),
133.3 (C), 139.0 (C), 144.3 (CH), 144.6 (C), 152.0 (CH), 157.3 ppm (C);
LC/MS (ESI ): tR=1.24 min, m/z (%): 305.2 (100) [M H]
 ; HRMS-
ESI: m/z [M+H]
+ calcd for C16H15N6O: 307.1302, found: 307.1296.
4-((1-Methyl-1H-benzo[d][1,2,3]triazole-6-yl)(1H-1,2,4-triazol-1-
yl)methyl)phenyl sulfamate (51): As method C using ClSO2NH2
(0.45m, 5.0 mL), DMA (2.5 mL) and 50 (0.11 g, 0.36 mmol). Purifica-
tion using a Flashmaster II (CH2Cl2/acetone) gave 51 as a white
solid (0.12 g, 84%):
1H NMR (270 MHz,[ D 6]DMSO): d=4.27 (3H, s,
CH3), 7.26–7.39 (6H, m, ArH and CH), 7.72 (1H, s, ArH), 8.00 (2H, s,
NH2), 8.05 (1H, d, J=8.8 Hz, ArH), 8.13 (1H, s, NCHN), 8.66 ppm
(1H, s, NCHN);
13C NMR (100 MHz,[ D 6]DMSO): d=34.3 (CH3), 64.9
(CH), 110.0 (CH), 119.4 (CH), 122.5 (2CH), 124.4 (CH), 129.7 (2CH),
133.4 (C), 137.0 (C), 138.1 (C), 144.7 (C, CH), 149.8 (C), 152.2 ppm
(CH); LC/MS (ESI ): tR=1.23 min, m/z (%): 384.4 (100) [M H]
 ;
HRMS-ESI: m/z [M+H]
+ calcd for C16H16N7O3S: 386.1030, found:
386.1013.
(R)-4-(2-(3-Bromo-4-hydroxyphenyl)-1-(1H-1,2,4-triazol-1-yl)e-
thyl)benzonitrile (17a): Separation of 17 on a Chiralpak AD-H
(250 20 mm) semi-prep column as described in the text gave
17a: t1=7.92 min; ½a 
20
D = 18.78 (c=0.89 in EtOH).
(S)-4-(2-(3-Bromo-4-hydroxyphenyl)-1-(1H-1,2,4-triazol-1-yl)e-
thyl)benzonitrile (17b): Separation of 17 on a Chiralpak AD-H
(250 20 mm) semi-prep column as described in the text gave
17b: t2=15.96 min; ½a 
20
D =+25.18 (c=0.90 in EtOH).
(R)-2-Bromo-4-(2-(4-cyanophenyl)-2-(1H-1,2,4-triazol-1-yl)ethyl)-
phenyl sulfamate (18a): Prepared from 17a as described for ( )-
18: ½a 
20
D = 15.98 (c=4.1 in EtOH).
(S)-2-Bromo-4-(2-(4-cyanophenyl)-2-(1H-1,2,4-triazol-1-yl)ethyl)-
phenyl sulfamate (18b): Prepared from 17b as described for ( )-
18: ½a 
20
D =+16.58 (c=3.1 in EtOH).
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